University of Connecticut

OpenCommons@UConn
Doctoral Dissertations

University of Connecticut Graduate School

7-28-2020

Influence of Local pH Environment and Zn(II) on the Structure of
the Antimicrobial Peptide Clavanin A and its Dynamics with
Different Membrane Models in MD Simulations
Searle Aichelle Duay
University of Connecticut - Storrs, searle.duay@uconn.edu

Follow this and additional works at: https://opencommons.uconn.edu/dissertations

Recommended Citation
Duay, Searle Aichelle, "Influence of Local pH Environment and Zn(II) on the Structure of the Antimicrobial
Peptide Clavanin A and its Dynamics with Different Membrane Models in MD Simulations" (2020).
Doctoral Dissertations. 2593.
https://opencommons.uconn.edu/dissertations/2593

Influence of Local pH Environment and Zn(II) on the Structure of the
Antimicrobial Peptide Clavanin A and its Dynamics with Different
Membrane Models in MD Simulations

Searle Aichelle S. Duay, PhD
University of Connecticut, 2020

In the latest report from the Centers for Disease Control and Prevention (CDC) on
antimicrobial resistance, this problem remains to be an urgent global threat, infecting
about three million people and killing about 36,000 people in the United States annually.
Antimicrobial peptides (AMPs) offer a number of advantages over small molecule
antibiotics, such as their structural flexibility in response to different local environments,
allowing for having environment-responsive modes of action. In this dissertation, we will
focus on Clavanin A (ClavA), an AMP that was identified and can be extracted from the
tunicate Styela clava. Experimentally, it was shown that ClavA acts via different
mechanisms at different pHs, pointing to a more membrane-active mechanism at pH 7
than at pH 5. Its antimicrobial activity is also enhanced by 16-fold in the presence of Zn2+
ions. In Chapter 2, we used unbiased molecular dynamics (MD) simulations to explore
the structure of ClavA and its interaction with different membrane models of Escherichia
coli in different environments. It was shown that the gain in positive charge increases
electrostatic attraction between ClavA and the negatively charged model membrane. We
proposed the domino-effect model showing how Zn2+ enhances the initial attraction of

Searle Aichelle S. Duay
University of Connecticut, 2020
ClavA to the model membrane. In Chapter 3, we explored different enhanced sampling
techniques to generate pathways of ClavA translocation across a more complex model
of an E. coli outer membrane. The advantages and disadvantages of using these
techniques in novel AMP-membrane systems were described. The free energy profiles
constructed from Hamiltonian replica exchange simulations showed that monomeric
translocation of ClavA across the model membrane is unlikely. In Chapter 4, we used
principal component analyses with bacterial cytological profiling to identify the
mechanisms enforced by ClavA under different environmental conditions. In Chapter 5,
the applicability of metadynamics in a different protein-metal ion system was showcased.
This dissertation is a significant contribution to complement the existing body of empirical
knowledge on Clavanin A. Through this work, we have exposed the strengths and
limitations of using molecular dynamics simulations in metal ion-binding AMPs, which is
an exciting set of AMPs that can be further studied.
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Chapter 1

General Introductions

Antimicrobial Peptides and their pH-dependent activities, Binding Transition
Metal Ions, and Different Molecular Dynamics Simulation Techniques

1

The Role of Antimicrobial Peptides in Addressing Antimicrobial Resistance
For about a decade, antimicrobial resistance has been a global challenge to public
health. In 2019, it was listed by the World Health Organization as one of the health issues
that demands attention, along with influenza, dengue, and HIV. 1 Antimicrobial resistance
happens when microbes, such as bacteria, fungi, and viruses, develop resistance against
antimicrobial drugs due to frequent exposure to the drugs. Aside from humans, it also
affects animals and the environment, especially in low- and middle-income countries.2-3
This can have a negative impact in the economy by the decrease in healthy livestock and
plants available for consumption.
To address this problem, antimicrobial peptides (AMPs) are being studied to
design and develop peptide-based drugs that will slow down antimicrobial resistance
development and/or kill antimicrobial-resistant microbes. AMPs are short sequences of
amino acids, typically ranging from 20 to 100 amino acids, that are naturally produced by
almost all organisms as part of their innate immune system. 4-9 Upon production, they act
as the organism’s first line of defense against pathogenic bacteria, killing through either
membrane disruption or action on an intracellular target.8-13 Due to their small size, AMPs
usually lack defined secondary structure (i.e. intrinsically disordered) in solution.
Formation of secondary structures will be marginally stable, if not unstable, because of
the loss of configurational entropy upon folding.14 Upon interaction with the target
membrane, conformational transition from random coil to helical structures is often
observed.15-16 However, some AMPs can form stable β-sheets in solution, and in some
cases stabilized by disulfide bonds or cyclization of the peptide backbone.17-18 In general,
AMPs can be classified into four secondary structure classes: α-helix, β-hairpin structure
2

Figure 1.1. Structural diversity of antimicrobial peptides. While most AMPs such as magainin 2 and LL37 are α-helical in the presence of a membrane, there are AMPs that adapt β-sheet conformations stabilized
by disulfide bridges (shown in yellow licorice). There are also a few peptides that do not contain significant
amount of secondary structures.

3

or loop, anti-parallel β-sheet, and disordered peptides (Figure 1.1).19 Because of the rich
diversity in structural conformation of AMPs, the relationship between their conformation
and their mechanism of action, including activity, is still not well-understood.
As most AMPs are cationic, the electrostatic attraction between the AMP and
negatively charged lipids in the target membrane drives their initial interaction. 14, 20-23
Natural amino acids that can be protonated at neutral pH to become positively charged,
such as arginine and lysine, are abundant in AMPs. The antimicrobial activity of the
peptides AKK24 and ARK24 are abolished upon mutation of the lysine and arginine
residues with histidines.24 Interestingly, trained artificial neural networks reveal that most
active AMPs contain a feature of having consecutive pairs of tryptophan residues with
interspersed arginine and lysine residues.4 AMPs will bind to the membrane and will
accumulate at a local region in the membrane. As multiple peptides accumulate on the
membrane, they may self-associate and oligomerize dependent on the AMP and
membrane properties.25-26 This leads to membrane destabilization by forming barrel-stave
pores27, toroidal pores28-29, or by covering the membrane like a carpet, followed by
micellization (known as the carpet mechanism) 13, 30-34 (Figure 1.2). All these processes
lead to the disruption of the cell membrane, promoting leakage of cellular contents that
are important for the survival of the cell, eventually leading to cell death. In the ShaiMatsuzaki-Huang model of antimicrobial activity of AMPs, the peptides get integrated into
the lipid bilayer, resulting into thinning and surface expansion of the outer leaflet. 13, 19, 3536

Due to the strain in the bilayer, it can undergo phase transitions, 36 and can form a

wormhole and transient pores.13, 35 AMPs can enter these pores and be transported to
the inner leaflet of the bilayer.35 Once a critical local concentration of AMPs surrounding

4

Figure 1.2. After the initial attraction of an antimicrobial peptide to the cell membrane, it can kill either by membrane disruption (left) or by
binding to internal cell targets (right) that will inhibit important cellular processes.

5

the pore is reached, micellization will occur.13 In some cases where micellization did not
occur, the peptides on the inner leaflet of the bilayer can diffuse and act on an intracellular
target. Bacteria can develop resistance against membranolytic mechanisms of AMPs by
modifying their membrane composition.37-38
While some AMPs are able to kill bacteria upon membrane interaction by
disruption, there are other AMPs that can easily penetrate the cell by forming transient
pores39-41 or translocating via receptor-mediated processes.42-43 After these AMPs are
internalized by the cell, they exert their antimicrobial activity by binding to intracellular
components such as DNA,44-45 DnaK (a bacterial chaperone protein),46 RNA,45
ribosomes,47 lipid II precursors,48 and GroEL protein (Figure 1.2).49-51 There are also
AMPs that inhibit various intracellular mechanisms,50-51 including protein synthesis,47, 52
DNA synthesis,53 and cell wall synthesis.48 Non-membranolytic mechanisms of killing in
AMPs offer a therapeutic advantage, as these slow down the development of
antimicrobial resistance by having specificity towards their intracellular targets.50 Bacteria
can easily develop resistance to membranolytic AMPs by simply changing the
composition of their outer membrane and inner membrane, as seen in magainin-resistant
E. coli strains.37-38 This specificity also provides reduced cytotoxicity towards human
cells.51 Additionally, having a primary non-membranolytic mechanism can trigger a
secondary mechanism of inhibition of other intracellular process, making it more difficult
for the bacteria to induce resistance against these AMPs. 50 An example of such AMP is
PR-39, which inhibits synthesis of proteins responsible for DNA replication54 and also
inhibits DNA synthesis.54

6

pH dependent-Antimicrobial Activity
There is a significant number of peptides, both from vertebrates and invertebrates,
that are known to have pH-dependent antimicrobial activities.55 Changes in the pH of the
local environment causes changes in the protonation states of residues in the AMPs, and
can induce changes in the secondary structure in AMPs. Different chemical and structural
features of AMPs such as charge, amphipathicity, hydrophobicity, and secondary
structure can all influence how they interact with both human cells and pathogenic
bacterial cells. These features can lead to the selectivity of AMPs towards Gram-negative
and/or Gram-positive bacteria. For example, gaduscidin-1 and gaduscidin-2, which are
both AMPs produced by the Atlantic cod Gadus morhua, undergoes a decrease in αhelicity under acidic conditions, as compared to when it is in a neutral pH environment.56
Interestingly, both peptides have decreased minimum inhibitory concentration (MIC)
against E. coli and increased cytotoxicity against carcinoma cells at a lower pH, with more
pronounced effects for Gad-2.56 These peptides are rich in histidines (pKa = 6.5) that are
mostly protonated at a lower pH, causing strong electrostatic repulsion and breakage of
hydrogen bonds that stabilize the α-helical structure. The loss of secondary structure is
compensated by increase in the positive charge of the peptide, leading to the
enhancement in electrostatic interaction of the peptide with an anionic bacterial
membrane.57 This seems to indicate that a favorable interaction between the bacterial
membrane and the AMP enhances its activity. However, having a very high affinity
towards the bacterial membrane can also negatively affect the activity, such as in
chensinin-1, an AMP from the Chinese brown frog Rana chensinensis.58 This peptide
showed antimicrobial activity against the Gram-positive bacteria Staphylococcus aureus,

7

but does not exhibit any significant activity against the Gram-negative bacteria E. coli.
Gram-negative bacteria have an inner membrane and an outer membrane, while Grampositive bacteria only have one cell membrane. The outer membrane of a Gram-negative
membrane has lipopolysaccharides (LPS) in the outer leaflet of the lipid bilayer. LPS
molecules are highly negatively charged and causes very strong electrostatic interactions
with the highly positive chensinin-1, even at a neutral pH. It was proposed that this strong
affinity towards the outer membrane prevents the inhibition of the peptide to cross the
membrane and enter the cell, abolishing the antimicrobial activity of the peptide. 59
The pH-dependent antimicrobial activity of some AMPs seems to be correlated
with the proton concentration of the location in which they were naturally produced or
secreted. For example, KS-30 and RK-31 are peptides that are produced in human sweat.
The acidic conditions in human sweat causes proteolytic cleavage to produce LL-37, thus,
protecting the human skin from fungal infection. 60 These peptides are derivatives of the
LL-37 AMP and have antifungal activity against Candida albicans. 60 Clavanins and
styelins are families of AMPs from the tunicate S. clava, and are extracted from the
hemocytes of the organism.61-62 These peptides have demonstrated enhanced
antimicrobial activity at a lower pH, which happens to be the same acidic environment in
the hemocytes of the tunicates.9, 62-63
Transition Metal Ions in Antimicrobial Peptides
Metal ions are the most common cofactors of biological enzymes. They are
abundant in all living organisms and they play an important role in various biological
functions, such as biocatalysis through metalloproteins 64-66 and immunity.5, 67-69 Iron and
zinc ions, for example, can regulate expression of metal transporters in the bacterial
8

pathogen, Corynebacterium diphtheriae,70 whereas zinc and manganese ions are
necessary to prevent the growth of the fungus Aspergillus fumigatus during corneal
infection.67 In the past few years, interest in the role of copper and zinc ions in the innate
immune defense against bacterial pathogens has seen increased attention. 68
Metal ions have the ability to coordinate both the enzyme and substrate, controlling
the orientation for the chemical reaction to occur; thereby, speeding up the reaction. They
can also be responsible for the proper folding of enzymes into their stable native states.
Therefore, it is not surprising that metal ions also play a role in the enhancement of activity
of AMPs. There are a number of AMPs that are identified to form complexes with metal
ions (Figure 1.3). Bacitracin is a cyclic dodecylpeptide that can bind Co 2+, Cu2+, Mn2+,
Ni2+, and Zn2+ (Figure 1.3A) via coordination to different residues. 71 Despite the weak
binding affinity of bacitracin to Zn2+ relative to other divalent cations, the Zn2+-bacitracin
complex has the highest binding affinity to pyrophosphates to inhibit bacterial cell wall
synthesis.72 Vancomycin binds Cu2+ ions in two different fashions (Figure 1.3B and 1.3C):
both having square-planar coordination with three nitrogen atoms and one oxygen atoms,
but they differ with the additional atoms from the peptide that are coordinated to Cu2+.73
While identifying the structural conformation or coordination geometry of the AMPmetal ion complex is an interesting area of research, rational design of metal-binding
AMPs (or metalloAMPs) can be advanced by identifying sequence motifs that can bind
metal ions and enhance the antimicrobial activity of the AMPs. An interesting set of
metalloAMPs are AMPs that contain the Amino Terminal Copper and Nickel (ATCUN)binding motif. This motif has the sequence H2N-XXH, wherein the first two amino acids
from the N-terminus of the peptide can be any amino acid and the third amino acid is a
9

Figure 1.3. (A) Crystal structure of bacitracin coordinated to Zn 2+. Nitrogen atoms from Ile1 and Cys2, and
oxygen atoms from D-Glx4, geranyl-pyrophosphate, and water form an octahedral complex with Zn 2+ (H
atoms in H2O molecule are omitted for clarity). (B, C) Molecular structure of vancomycin complexed with
Cu2+ ions. In (B), Cu2+ is coordinated to a water molecule apart from four residues in vancomycin. In (C),
an additional nitrogen atom is coordinated to Cu 2+. Reprinted from Journal of Inorganic Biochemistry, Vol.
102, Kucharczyk, M.; Brzezowska, M.; Maciag, A.; Lis, T.; & Jeżowska-Bojczuk, M., Structural features
of the Cu2+–vancomycin complex, Pages 936–942, Copyright 2020, with permission from Elsevier.

histidine. It is known to bind Cu2+ and Ni2+ ions by coordinating the nitrogen from the Nterminus, two nitrogen atoms from the amide backbone, and nitrogen atom from His3, in
a distorted square planar geometry.74 Histatins are a family of histidine-rich peptides that
are active against C. albicans.75 Most of the peptides belonging to the histatin family
contain the ATCUN motif and can bind Cu2+ and Ni2+ ions in different affinities. Binding of
Cu2+ ions induces generation of reactive oxygen species (ROS) that cause cell death. 75
10

Aside from Cu2+ and Ni2+, it can also bind other ions such as Zn2+ and Fe2+.76-77 However,
it was shown that binding Fe2+ to the ATCUN motif of histatins leads to significant
decrease in its α-helicity and antifungal activity.77
Recently, another metal-binding motif known as the HXXXH motif was observed
to bind metal ions such as Zn2+ and results into an increase in the antimicrobial activity of
HXXXH-contaning AMPs. This motif was first identified as a zinc-binding consensus
sequence in calcitermin, an AMP that is isolated from human airway secretions. 78 In the
presence of Zn2+ ions, its antimicrobial activity increases against E. coli and Listeria
monocytogenes.78 Clavanin A, a member of the clavanins family, is another AMP that
contains the HXXXH motif and was observed to have a 16-fold increase in antimicrobial
activity against E. coli in the presence of Zn2+ ions.9 However, there are peptides
containing the HXXXH motif that have not yet been studied to bind transition metal ions
or to enhance their antimicrobial activity in the presence of these ions.79-83 It is, therefore,
important to understand the role of this motif in the structure and membrane interactions
of AMPs that have increased antimicrobial activity upon binding to transition metal ions.
Molecular Dynamics Simulations
The large interest in identifying and developing AMPs into therapeutic molecules
have caught the attention of computational scientists who use in silico approaches to
understand the mechanism and behavior of AMPs in solution and in the presence of
different membrane environments. Different models of membrane disruption (Figure 1.2),
including pore formation29, 84-87 and carpet mechanism13, 33-34, have been proposed from
experimental results but these are not fully understood. Observing the molecular motions
of a single molecule is a challenging, if not impossible, task to experimentalists. This led
11

to using molecular dynamics (MD) simulations as a “molecular microscope” to understand
the dynamics of a single molecule of an AMP and the dynamics of multiple AMPs in
various environments.
In a classical MD simulation, an initial set of coordinates of the atoms in the system
is supplied. Each set of coordinates can be referred to as a snapshot. The potential
energy of each atom is calculated from its interactions with other atoms and the
parameters supplied by the chosen force field. These interactions can generally be
classified as bonded or non-bonded interactions (Figure 1.4). Bonded interactions consist
of covalent bonds between atoms, bond angles, dihedral angles, and improper torsions.
Non-bonded interactions consist of electrostatic interactions and van der Waals
interactions, typically modeled by a Lennard-Jones potential. The force experienced by
each atom can then be calculated from the negative gradient of the potential energy.
Through a series of integrations of the Newton’s equation of motion, the coordinates of
each atom after a chosen timestep (usually in the range of 1 to 2 femtoseconds for allatom models) is calculated. The new coordinates of each atom will then be used to
recalculate the new potential energies, and the series of calculations previously described
is iterated multiple times. This generates a time series of snapshots that will show the
dynamics of the system. If the simulation is done long enough, the simulation should be
able to sample the Boltzmann distribution and explore all the possible conformations for
the system. However, the current technology on computational resources is not powerful

12

Figure 1.4. The potential energy of the system is the summation of all bonded potential energy terms (blue) and non-bonded potential energy
terms (red). The bonding potential energy terms are the covalent bonds, bond angles, dihedrial angles and improper torsions, while the nonbonded
potential energy terms are the Coulomb potential and the Lennard-Jones 12-6 potential.
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enough to do this. As the energy barrier to go from one energy minimum to another energy
minimum becomes greater than 1 𝑘𝐵 𝑇, where 𝑘𝐵 is the Boltzmann constant and 𝑇 is
temperature, the probability of crossing the energy barrier becomes less (Figure 1.5).
Thus, computational techniques that allow enhanced sampling were developed to
address this problem, which will be discussed in more detail in the next section.

Figure 1.5. (A) Example of a potential surface of a system along two collective variables. The initial state
of the system is highly energetic (shown in gold sphere). Throughout the simulation, the system will explore
different conformations along the collective variable favoring those with low energy. Shown as orange and
purple arrows are possible pathways for the system leading to different low energy conformations. (B) The
probability of a system to be in a certain state is proportional to the energy in that state, following the
Boltzmann distribution.
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MD Simulations in Antimicrobial Peptides
There are several considerations in designing MD simulations to study
antimicrobial peptides. One would be the lipid composition of the model lipid bilayer. A
significant number of simulations use lipid bilayers composed of phosphatidylcholine
(PC), a zwitterionic lipid, or phosphatidylglycerol (PG), an anionic lipid, or a combination
of both.88-92 Another would be the force field to be used in the simulation. There is no clear
agreement in which force field gives the most accurate results for peptide-membrane
systems. Force fields such as Chemistry at Harvard Macromolecular Mechanics
(CHARMM) and Assisted Model Building with Energy Refinement (AMBER) are both
reliable for protein systems. Many MD simulations use the CHARMM force field for lipidcontaining systems as it is continuously parametrized for lipids. 93-94 In a comprehensive
review article, experimentally determined properties such as NMR CH order parameters
of glycerol backbone and membrane partitioning free energy of small molecules are more
consistent with calculations resulting from simulations using the CHARMM force field.95
Using different force fields can yield different results and, thus, requires experimental
results to validate which models are more accurate.96
Magainin 2 is an AMP that is well-known to form membrane pores leading to
bacterial cell death.29,

84-86, 97

The proposed pore formation model starts from

accumulation of monomers and dimers of the peptide on the outer leaflet of the lipid
bilayer, causing expansion of the leaflet.85 As the leaflet relaxes, some of the peptides
are brought into the bilayer, forming the transmembrane channel-like tetrameric or
pentameric pore structure.84-85 These pores are characterized as transient pores, due to
their short lifetime.84-85 Through microsecond-long equilibrium MD simulations, more
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properties of the pore were suggested, such as having an inner radius of about 3 to 8 Å
for a tetrameric pore.88 This range of values is less than the experimental values from
neutron scattering29, cryo-EM98, and confocal laser spectroscopy99 studies. This suggests
that the pores observed experimentally are in a much higher oligomerization state than a
tetramer. Tilted peptides were also observed from the MD simulations, suggesting a
toroidal pore, rather than a barrel-stave pore.88
Enhanced Sampling Techniques
Monitoring the molecular interactions and motions of a biomolecule on an atomistic
level cannot be done using any experimental technique. Solving the structure using NMR,
X-ray diffraction, or cryo-EM only reveals one conformation, and cannot show the different
conformations along the pathway of interest. As discussed earlier, MD simulations can
address this limitation; however, running an unbiased MD simulation may lead to the
system being trapped in an energy well, prohibiting the system to explore other
conformations. To overcome this problem, computational techniques such as
metadynamics (METAD), umbrella sampling (US), and Hamiltonian replica exchange
(HREX) simulations were developed to enhance conformational sampling and/or focus
sampling on a specific pathway. In these techniques, bias energies are introduced to force
the system to explore conformations along a chosen variable (referred to as a collective
variable), which is a function of the atomic time. Moreover, the energy changes along the
collective variable may be calculated using these techniques.
In running metadynamics simulations, one requires to define at least one collective
variable (CV), also known as reaction coordinate, that can be explored to capture the
transitions along the desired pathway. History-dependent biases are regularly deposited
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along the CV space to build up the bias potential and allow the system to explore other
conformations which are rarely or have not yet been explored (Figure 1.6). 100 As bias
energy builds up in a local energy minimum, it will push the system out of that minimum
to explore other regions of the phase space.100 Eventually, the bias potential will fill up all
local minima and the inverse of the bias can be used to calculate the free energy surface
of the system along the defined CV(s).100 A variation of METAD called frequency adaptive

Figure 1.6. (top) Time evolution, in terms of number of Guassians deposited, of the collective variable
throughout the metadynamics simulation. (bottom) Sum of the bias potential added and the underlying
potential (thick lines) are shown as thin lines. The free energy surface are filled continuously through time.
Reprinted from WIREs Computational Molecular Science, Vol. 1, Barducci, A.; Bonomi, M.; & Parrinello,
M., Metadynamics, Pages 826–843, Copyright 2020, with permission from Wiley.
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metadynamics can be used to obtain smoother transitions between local minima. 101 In
this technique, the frequency of bias addition is decreased as the system approaches the
maxima of the energy barrier.101 The bias potential that is added is in a form of a Gaussian
curve, with parameters σ and W, defining the width and height of the hill, respectively.
The bias added at a specific time is calculated using102:
2

𝑑
(𝑆𝑖 (𝑅) − 𝑆𝑖 (𝑅(𝑡 ′ )))
𝑊
′
𝑉𝐺 (𝑆, 𝑡) = ∫ 𝑑𝑡
exp (− ∑
)
𝜏𝐺
2𝜎𝑖2
0
𝑡

𝑖=1

where 𝜏𝐺 is the bias deposition stride, 𝑆𝑖 (𝑅) is the set of microscopic coordinates 𝑅 in the
𝑖th CV, 𝑑 is the number of defined CV, and 𝑡′ is the timestep.
Another computational technique that can be used to extensively sample a
pathway is Hamiltonian replica exchange (HREX) MD simulations. Similar to umbrella
sampling, a pathway along a CV is required for HREX and can be generated either by
steered MD, or other methods. Different points along the pathway of interest, including
the starting point and end point, will be extracted as replicas. Each replica will have a
modified Hamiltonian consisting of the unbiased potential energy and a bias harmonic
potential centered along the initial value of the CV. The results from HREX is less
dependent on the choice of CV, as compared to the dependence of the results from US
on the CV choice.103
⃗ ), of exploring the configuration in each replica with a
In HREX, the probability, 𝑃(𝒓
⃗ , is
set of coordinates 𝒓

⃗ ) ∝ exp (−
𝑃 (𝒓
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⃗)
𝑈 (𝒓
)
𝑘𝐵 𝑇

⃗ ) is the modified Hamiltonian of the replica, 𝑘𝐵 is the Boltzmann constant, and
where 𝑈(𝒓
𝑇 is the temperature of the system. The replicas are simultaneously run for a certain
number of timesteps before an exchange between two replicas is attempted. Ideally, the
simulation time before an exchange is attempted should be long enough to allow
equilibration of the slowest degree of freedom in the system. In the event of an exchange
attempt between two replicas, the acceptance value α will be calculated based on the
probabilities of each configuration using their original Hamiltonians and the probabilities
of each configuration using the Hamiltonian of the other replica. This acceptance value
indicates the probability of the two replicas to be exchanged. Mathematically,

𝛼 = min (1, exp (

⃗ 𝑖 ) + 𝑈𝑗 (𝒓
⃗ 𝑗 ) − 𝑈𝑖 (𝒓
⃗ 𝑗 ) − 𝑈𝑗 (𝒓
⃗ 𝑖)
𝑈𝑖 (𝒓
))
𝑘𝐵 𝑇

For an efficient exchange between replicas, there must be an overlap in their sampled
potential energies (Figure 1.7B). If the potential energies do not overlap (Figure 1.7A),
there will be no exchanges and the pathway of interest will not be sampled extensively.
This will plainly be independent simulations run with different Hamiltonians.104 An
exchange will occur if the potential energies of the replicas with exchanged Hamiltonians
are less than the potential energies with their original Hamiltonians. Otherwise, the
probability of exchange will be inversely proportional to the energy difference of the two
systems (Figures 1.7C and 1.7D).
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Figure 1.7. Different scenarios of potential energy overlap between two replicas: (A) no overlap, and (B) ideal overlap. (C) If the energies of
the replicas increase after exchange, the probability of exchange is inversely proportional to the energy difference between the systems. (D)
Otherwise, there is a 100% probability of exchange.
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Energetics of pore formation in AMPs can also be calculated using umbrella
sampling. The free energy of melittin reorientation from a membrane-bound state to a
transmembrane state, for example, was evaluated by performing US simulations. 105
Temperature replica-exchange molecular dynamics (T-REMD) simulations were also
used to evaluate free energy of folding of met-enkephalin1 1 and to describe the
mechanism of binding of Alzheimer Aβ10-40 peptide to DMPC bilayers106, both of which
are not antimicrobial peptides. The feasibility of conducting enhanced sampling
simulations in peptides can be extended to AMPs to further explore conformations of
AMP-membrane systems that have high energy barriers and cannot be explored by
equilibrium MD simulations.
Overview of the Dissertation
Clavanin A (ClavA) is an antimicrobial peptide (VFQFLGKIIHHVGNFVHGFSHVFNH2) that contains lysine and histidine residues, making it highly cationic at low pH. This
peptide, along with other clavanins, are found in the hemocytes of Styela clava which has
an acidic pH of 5.0.107 It has significantly greater antimicrobial activity against E. coli,
Listeria monocytogenes, and Candida albicans at an acidic pH of 5.5 than the human
physiological pH of 7.4.108 Due to the abundance of His residues (pKa ~ 6) in ClavA, the
peptide has different protonation states at acidic pH and at neutral pH, which are both
biologically relevant. In Chapter 2, we explored how the different protonation states of
ClavA affect its mechanism of action that results into different antimicrobial activities.
Particularly, we conducted equilibrium MD simulations to understand how the different
histidine protonation states influence the initial binding of ClavA to a simple model of an
E. coli outer membrane model. Experimentally, it was also observed that the presence of
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Zn2+ ions in the environment of ClavA enhanced its antimicrobial activity. 9 This was not
observed in the H17A and H21A mutants, suggesting that Zn2+ binds to the HXXXH motif
which causes the increase in activity.9 Thus, we also studied how Zn2+ binding to the
HXXXH motif affects the peptide interaction with the model membrane.
Current computational power is not sufficient for equilibrium MD simulations to
timescales where translocation events of ClavA across the model membrane occur. In
Chapter 3, we used enhanced sampling techniques in MD simulations that allow us to
explore different translocation pathways. These techniques introduce biases, in the form
of potential energies, into the system that will favor translocation. The advantages and
disadvantages of using steered MD and metadynamics simulations in searching for these
pathways were compared. The importance of choosing the collective variable to bias were
also highlighted, as this provides different pathways that have varying free energy
profiles. We employed another enhanced sampling technique called Hamiltonian replica
exchange (HREX) to generate these profiles. A more realistic model of the E. coli outer
membrane was made by using purely lipid A molecules on the outer leaflet and a mixture
of PE, PG, and cardiolipin lipids on the inner leaflet. Heterogeneous lipid bilayers were
not historically commonly used in all-atom MD simulations due to their complexity. Thus,
one highlight in this dissertation is the use of enhanced sampling techniques in a system
containing an AMP and a heterogeneous lipid bilayer. This allowed us to estimate the free
energy requirement of partitioning ClavA into the model bilayer in different protonation
states.
In Chapter 4 of this dissertation, it was shown how statistical analyses such as
principal component analysis (PCA) can be used as a tool to identify the mechanism of
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action of ClavA in different conditions. PCA is used to analyze results from cytological
profiles of bacterial cells after they were exposed to different antibiotic molecules,
including ClavA. In Chapter 5, we used metadynamics as a powerful tool to explain the
experimentally observed binding affinities of different inhibitors of an E. coli enolase, and
the role of Mg2+ ions in stabilizing these binding interactions.
The encompassing theme in this dissertation is to feature how different MD
simulation techniques can be used to study the interaction of proteins, mainly
antimicrobial peptides, with different systems such as lipid bilayers and small molecule
inhibitors. This dissertation contributes to the growing body of knowledge of Clavanin A
as a potential therapeutic molecule. To our knowledge, this is the first time that an
extensive set of computational studies were done on ClavA to investigate its mechanism
of action on an atomistic scale. We hope to increase the interest of the community in
using MD simulation as a tool to understand interactions of AMPs with different biological
systems. The findings from such computational studies will contribute in the development
of AMPs as therapeutics.
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Introduction
ClavA is a cationic and amphipathic 23-amino acid peptide that is active against a
broad spectrum of pathogens in vitro, including methicillin-resistant Staphylococcus
aureus, with a maximal activity at pH 5.5.1 More significantly, ClavA has exhibited efficacy
against an in vivo S. aureus wound model, with low to no cytotoxicity in mammalian cells,
suggesting that ClavA can be used for novel peptide-based therapeutic strategies in
treating wound and sepsis infections.2 Clavanin A (ClavA) was shown to have a 16-fold
increase in antimicrobial activity against Escherichia coli in the presence of Zn(II) ions.3
The HXXXH motif located from positions 17−21 in ClavA, where X is any canonical amino
acid, is known to form a putative binding site for transition metal ions, including Zn(II). 4-5
To our knowledge, there are no experimental or computational reports that investigate
Zn(II) binding on the structural properties of ClavA. Here, we investigate the hypothesis
that Zn(II) can act as a “staple” that can induce and stabilize helical conformations at the
Zn(II)-binding region of the peptide in an attempt to elucidate a structure−function
relationship for Zn(II)-bound ClavA.
All-atom classical molecular dynamics (MD) simulations have been widely used to
investigate how AMPs behave, both in solution and in the presence of model
membranes.6-10 Because of limitations in computational power, some MD simulations fail
to reach relevant time scales or sample the relevant configurational space and therefore
are limited in their ability to provide complete and accurate information on the mechanism
of action of AMPs.11 However, computational studies are useful in providing various
insights that can guide experimental design efforts. Also, MD simulations are useful in
providing mechanistic insights by calculating energy landscapes for conformational
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transitions and the ability to observe high energy transition states that are difficult to
observe experimentally.12-13
In this chapter, we investigate the influence of Zn(II) on the conformational
properties of ClavA and its interaction with a general model for a gram-negative model
membrane. To our knowledge, this is the first time that classical MD simulations have
been used to investigate metalloAMPs in the presence of a two-component model
membrane. We show that Zn(II) can stabilize helical conformations in the Zn(II)-binding
region. We also find that Zn(II) provides more favorable electrostatics for the C-terminal
region of ClavA to interact with the membrane. Furthermore, we observe a critical
threshold for the molar ratio of Zn(II) to lipids that will induce increased lateral
deformability for the E. coli membrane model. With these insights, we present a model of
how Zn(II) affects the structure of ClavA and its overall interaction with the membrane.
Methodology
Simulation Models. The simulations of ClavA were initiated from helical and
extended conformations (Figure 2.1). The helical structure was determined by solutionstate nuclear magnetic resonance (NMR) PDB ID: 6C41,14 in which an α-helical segment
was observed from residues Phe2 to Val22. This structure was obtained in 35% 2,2,2trifluoroethanol (TFE)-d3, a solvent which provides a low dielectric constant similar to a
membrane, 10% D2O, and 55% buffer at pH 4.3. The extended structure was generated
using the PDB utilities server (https://spin.niddk.nih.gov/bax/). Chemical modifications to
the peptide were performed using CHARMM-GUI,15-17 which included C-terminal
amidation and protonation of histidines (His) in systems modeling a pH 5 environment
(Chart 2.1).
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Figure 2.1. Two simulation models of ClavA used as initial structures in the simulations: (A) helical and
(B) random coil. Residues are shown using a ball-and-stick model, with hydrophobic residues in blue and
hydrophilic residues in red.

The peptide models were solvated with the TIP3P water model and 150 mM NaCl.
Both the ordered and disordered peptide models were also simulated in the presence of
a Gram-negative bacterial membrane model.18-19 The membrane model consisted of 1palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and 1-palmitoyl-2-oleoylsn-glycero-3phospho-(1′-rac-glycerol) (POPG) lipids. The membrane contained 120 lipids
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Chart 2.1. Illustration of the Peptide Models Used in the Simulations and Their Shorthand Names in
the Papera

a

There is one Lys and four His residues that can titrate depending on the system pH. His residues are

protonated at pH 5, except when these residues are bound to Zn(II).

(60 in each leaflet) with a ratio of 80:20 POPE/POPG. The peptide models were initially
placed approximately 3 nm above the membrane. The peptide−membrane system was
generated by using the CHARMM-GUI server.15-17
Energy minimization and equilibration steps were performed according to the
CHARMM-GUI protocol, employing the steepest descent minimization for 500 steps and
a canonical ensemble equilibration for 25 ps with a timestep of 1 fs for the helical ClavA
in solution simulations. For the ClavA in the presence of a membrane model, three
successive canonical ensemble equilibrations for 25 ps (1 fs timestep) followed by three
successive isothermal−isobaric ensemble equilibrations for 50 ps (2 fs timestep) were
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employed. Semi-isotropic pressure coupling was used to generate a zero surface tension
ensemble using the Berendsen barostat. During the equilibration steps, positional
restraints on protein heavy atoms and lipid phosphorus atoms were employed. Dihedral
restraints were placed on the lipid glycerol and tail moieties around the unsaturated bond.
The force constants for these restraints were gradually decreased after each equilibration
step.
For the helical ClavA in solution system, 3 independent MD simulations were
performed at 4 different temperatures (300, 320, 340, and 360 K), resulting in 12
independent simulations. Another set of 12 simulations were run for the helical ClavA with
Zn(II) bound to His17 and His21. Zn(II) was restrained by applying a distance restraint of
2.095 Å to each δ-nitrogen atom of the His residues, with a force constant of 20,710.8 kJ
mol−1 nm−2. These values were obtained by averaging the experimentally obtained
coordination length and force constant20 of Zn(II) to the nitrogen atoms of imidazole, an
analogue of histidine. The simulations were run for 100 ns each using a timestep of 2 fs.
Temperature was maintained using a Nose−Hoover thermostat21-22 with a coupling time
constant of 1 ps. Pressure was maintained at 1 bar by implementing an isotropic pressure
coupling scheme using the Parrinello−Rahman barostat with a coupling constant of 5
ps.23 Van der Waals interactions were cut off at 1.2 nm, with the interactions being
modified using the force-switch method between 1.0 and 1.2 nm. Long-range electrostatic
interactions were calculated using the particle mesh Ewald method, with a real-space
cutoff of 1.2 nm. The first 30 ns of the simulations were considered as further equilibration,
leaving the remaining 70 ns for analysis (Table 2.1).
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Table 2.1. Summary of Simulation Details
System
Initial
# of
Simulation Equilibration Analysis
Description Conformation simulations
length
time (ns)
time (ns)

Helical
stability
studies

Helical ClavA
in solution

P7(−), P5(−) Random coil
ClavA in
presence of
P7(+), P5(+)
model
membrane
hP7(−),
Helical ClavA
hP7(+)
in presence of
model
membrane
Zn(II) effect Model
on
membrane
membrane
with Zn(II) ions
properties
(no ClavA)

24

12

100 ns

500 ns

30

100

70

400

Total
sampling
(μs)

1.68

4.8

Temperature
(K)

pH

Zn(II)
bound
to
ClavA?

300
320
340
360

7

yes/no

300

7
5
7
5

no
yes

6

500 ns

100

400

2.4

300

7

yes/no

6

500 ns

100

400

2.4

300

7

N/A
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For the system containing ClavA in the presence of a membrane,
isothermal−isobaric ensemble simulations were run at 300 K for 500 ns. For each of the
conditions shown in Chart 2.1, triplicate simulations were conducted from a random coil
configuration. The pH 7 states (P7(+), P7(−)) were also simulated in triplicate starting from
a helical conformation. The temperature was maintained using the Nose−Hoover
thermostat21-22 with a coupling time constant of 1 ps, while a semi-isotropic pressure
coupling scheme was implemented using the Parrinello−Rahman barostat 23 with a
coupling constant of 5 ps. The lipid bilayer compressibility was set to 4.5 × 10−5 bar −1,
and the reference pressure in the bilayer plane (XY) and bilayer normal (Z) was set to 1
bar. Treatment of nonbonded interactions was consistent with ClavA in solution systems
described above. The first 100 ns of the simulation was considered as further
equilibration, leaving the remaining 400 ns for analysis.
Another set of simulations to investigate the effect of ClavA and Zn(II) on
membrane properties was also conducted. A total of six simulations with varying
Zn(II)/lipid ratios, specifically 0:120, 1:120, 1:60, 1:30, 1:15, and 1:7.5, were conducted.
The ions were placed approximately 3 nm above the upper leaflet of the membrane. To
keep the ions interacting with only the upper leaflet, a flat bottom restraint was applied 6
nm above the membrane. The systems were solvated in 150 mM NaCl and a TIP3P water
model. The production runs were performed in an isothermal−isobaric ensemble at 300
K and 1 bar for 500 ns. The temperature and pressure coupling parameters and the
nonbonded parameters used in the extended peptide−membrane simulations were also
used for the membrane-only simulations. The first 100 ns of the simulations were
considered as further equilibration, leaving the remaining 400 ns for analysis (Table 2.1).

38

All simulations were performed using the GROMACS 201624 program and the
CHARMM3625-26 force field. As a control simulation, the ability of the force field to maintain
the helical conformation in TFE was evaluated in a 100 ns MD simulation. A superposition
of the MD-equilibrated and NMR structures (PDB ID: 6C41) [root-mean-squared deviation
(rmsd) = 2.9 Å] showed that ClavA in TFE retained its overall secondary structure and
helicity during the simulation (Figure S2.1). The trajectories were visually analyzed using
VMD,27 and further quantitative analyses were performed using a combination of
GROMACS tools, MDTraj,28 and in-house Python scripts.
Membrane Properties Analysis. To evaluate the effect of ClavA and Zn(II) on the
structural and mechanical properties of membranes, the membrane thickness, area per
lipid, and area compressibility were measured as a function of Zn(II) concentration. The
membrane thickness was defined by the Z-coordinate difference between the center of
mass (COM) of the upper and lower leaflet phosphates. The area per lipid was calculated
by dividing the box area (in X−Y plane) by the number of lipids per leaflet (60). The area
compressibility modulus, KA, of the membrane was calculated from 29

𝐾𝐴 =

𝑘𝐵 𝑇𝐴
𝑁 ( 𝐴 − 𝐴0 ) 2

where N is the number of lipids in each leaflet, A and A 0 are the instantaneous and
equilibrium areas per lipid, respectively, kB is the Boltzmann’s constant, and T is the
system temperature. All membrane quantities were averaged over the final 400 ns of the
simulations (Table 2.1).
Statistical Analyses. All reported error estimates are standard errors. For all
analyses that required determination of the significant difference, the standard Welch’s t39

test was used for unequal variances. Survival probability analysis was also used to
determine the significant differences in association duration times. To summarize, this
analysis plots the probability of a region to stay bound before unbinding over some time
interval. Log rank test was used to compare the significant differences between survival
probability plots.
Results
Zn(II) Effects on ClavA α-Helical Stability in Solution
We examined the stability of an α-helical segment located at the Zn(II)-binding
region (His17 to His21) by running 100 ns simulations initiated from a helical configuration
of ClavA in 150 mM NaCl solution at four different temperatures: 300, 320, 340, and 360
K. For Zn(II)-bound ClavA systems, Zn(II) was bound by applying distance restraints to
the δ-nitrogens of His17 and His21. We observed that, on average, there are four ligands
coordinated to Zn(II) ions throughout the simulations at all temperatures (Figure S2.2). In
addition to the coordinating His δ-nitrogen atoms, two water molecule oxygen atoms are
found in the first coordination sphere of Zn(II). This is consistent with other Zn(II)-binding
proteins that bind Zn(II) in a tetrahedral fashion. 30-32 During the simulations, a decrease
in the average helicity of ClavA without Zn(II) as temperature is increased is observed as
expected, since high thermal energy can denature the peptide secondary structure.
Interestingly, we did not observe a consistent decrease in helicity in the ClavA−Zn(II)
complex as a function of increasing temperature (Figure 2.2A). At 340 K and above, the
average helicity of ClavA−Zn(II) remained at about 40% and did not further decrease in
the temperature range we examined. In contrast, ClavA without Zn(II) displayed
continuously decreasing helicity as the temperature increased. Moreover, at
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temperatures 320 and 360 K, our simulations showed significantly greater helicity when

Figure 2.2. (A) Average helicity of ClavA in the absence or presence of Zn(II) at four different
temperatures. Bars represent the average of three trials ± the standard error. Welch’s t-test: *p < 0.05. (B)
Final snapshots of representative trials at 360 K. The secondary structure of ClavA is shown, with the
Zn(II)-binding region represented in red, Zn(II) ion represented in gray, and His17 and H21 represented as
a ball-and-stick model. (C) Secondary structure evolution (DSSP analysis) of the same representative trials
at 360 K throughout 100 ns simulations.

Zn(II) was bound as compared to that of the Zn(II)-free peptide. The difference in helicity
between the two systems could possibly be due to the Zn(II)-binding region being
restricted to remain in an α-helical conformation. Looking at the snapshots at the end of
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the simulations of a representative trial at 360 K (Figure 2.2B), we observed that the
Zn(II)-binding region remains αhelical. To quantify our observations, we used the Define
Secondary Structure of Proteins (DSSP) algorithm analysis tool to calculate the most
probable secondary structures of each residue at 1 ns intervals (Figure 2.2C). In the same
representative trial, we observed that the α-helical conformation of the Zn(II)-binding
region is stable for the duration of the 100 ns simulations. The helical stabilization in Zn(II)bound systems was concluded from three independent trials at each temperature. The
secondary structure evolution for all simulations is presented in Figures S2.3−S2.10. We
observed stable helical conformations in regions other than the Zn(II)-binding region, but
the helical regions were not consistent across all trials. On longer time scales, we expect
that these helical conformations outside the Zn(II)-binding region will eventually
destabilize, whereas the region with the metal ion bound to it will remain helical.
Zn(II) Effects on ClavA α-Helical Stability in the Presence of a Membrane
To characterize which regions of ClavA have stable helical conformation in the
presence of a membrane, simulations were initiated with helical ClavA placed 3 nm above
the membrane. We observed that the residues near the C-terminal region, particularly
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residues His17 to Phe23, lose helicity as early as 80 ns (Figure 2.3A). In one of the trials

Figure 2.3. Secondary structure evolution of different peptide models in the presence of a gram-negative
bacterial model membrane: (A) ClavA only, (B) ClavA with Zn(II) restrained to His17 and His21, and (C)
ClavA with unrestrained 32 Zn(II) ions. The secondary structure evolution plots of the other replicates are
presented in the Supporting Information (Figures S2.11−S2.13).

(Figure S2.11), the same region was observed to lose helicity transiently for about 100
ns. It should be noted that the helicity in the N-terminal region is not very stable in the
presence of a membrane. The general observation in all our helical peptide−membrane
simulations is that the helicity in the central region, Ile8 to Val16, is more stable than in
the terminal regions. When Zn(II) was bound to His17 and His21 of ClavA, the helicity of
the C-terminal region increased, with it remaining helical for the full 500 ns in all three
simulations (Figures 2.3B and S2.12). This implies that Zn(II) provided helical stability to
the C-terminal region even in the presence of a membrane, as was similarly observed in
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solution. We also ran triplicate simulations of ClavA in the presence of a membrane but
with 32 free (unrestrained) Zn(II) ions in solution. The results were similar to the
ClavA−membrane system without Zn(II), where the terminal regions were not as stable
as the central region (Figure 2.3C). No sustained spontaneous formation of
Zn(II)−histidine coordination was observed in the free Zn(II) simulations.
We next examined whether Zn(II) influences the formation of a α-helical structure
in ClavA in the presence of a membrane by starting from a random coil conformation of
the peptide. The peptide was placed in the presence of the gram-negative bacterial
membrane model, composed of a 4:1 ratio of POPE and POPG lipids. AMPs have been
observed, both experimentally and computationally, to form ordered secondary structures
in the presence of a membrane because of favorable electrostatic interactions with the
lipid head groups and hydrophobic interactions with the lipid tails. 33-35
We did not observe any formation of a α-helical structure that can be attributed to
binding Zn(II) to ClavA (Figure 2.4). In the representative trial of ClavA at pH 7 (Figure
2.4A), P7(−), we observed the formation of α-helices and β-sheets outside the Zn(II)binding region for about 100 ns, but these conformations are short-lived and are not stable
throughout the simulation. On the other hand, in one trial of Zn(II)bound ClavA (Figure
S2.14), P7(+), we observed the formation of a stable α-helix outside the Zn(II)-binding
region, specifically from residues Lys7 to Val12. To determine whether Zn(II) could
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possibly have a long-range effect of inducing helix formation, we extended the simulation

Figure 2.4. Secondary structure evolution of representative 500 ns simulation trials initiated from a
disordered peptide in the presence of a membrane at neutral pH (A) and at acidic pH (B). Under both pH
conditions, simulations were conducted with and without Zn(II) bound to the peptide.

for an additional 500 ns and removed Zn(II). The helix remained stable even without the
Zn(II); hence, we do not attribute the helical formation to Zn(II) binding.
Because the activity of ClavA is greater at pH 5.5 than at pH 7, 1 we proceeded to
investigate helical formation under acidic conditions (P5(−) and P5(+) in Chart 2.1). The
simulations of the P5 systems showed no formation of helical structures (Figure 2.4B).
This observation indicates that having an additional four [from P7(−) to P5(−)] or two [from
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P7(+) to P5(+)] positive charges decreases the probability of forming ordered secondary
structures because of the increased electrostatic repulsion between the protonated
residues. However, we do not eliminate the possibility that pKa shifts occur as the peptide
inserts and interacts with lower dielectric regions of the membrane.
ClavA Membrane-Binding Analysis
Throughout 500 ns membrane-binding simulations (Figures 2.5 and S2.15−S2.26),
we observed that the Phe residues of ClavA insert the deepest into the membrane. Phe
residues reach a depth of 1 nm below the phosphate groups. In a previous study, mutation
of the Phe residues to other hydrophobic residues, such as isoleucine or tryptophan, did
not show any significant differences with the wild-type at low pH.36 Though this indicates
that Phe residues are not crucial at low pH, our simulations present a striking observation
that phenylalanines (Phe) can easily overcome the energetic barrier of crossing the head
group region of the membrane, and its hydrophobicity provides stabilization for these
residues to insert deeper into the hydrophobic region of the membrane.
At pH 5, binding of Zn(II) will effectively increase the net charge of the peptide from
+2 to +4, which we predict will lead to stronger electrostatic interactions and preferential
interaction of the C-terminal [Zn(II)-binding] region. It has been postulated that the
mechanism through which ClavA kills is distinctly different at pH 7 and at pH 5. 37 The
membrane is not efficiently permeabilized at low pH, suggesting a killing mechanism
where there is an internal cell target,3, 37 whereas at a physiological pH, the mechanism
involves nonspecific membrane permeabilization, possibly via a carpet model, indicating
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Figure 2.5. Insertion depths of the residues with respect to the COM of the upper leaflet phosphates.
Phenylalanine residues insert the deepest, indicated by red arrows. Data is from the last 50 ns of one trial
of the system without Zn(II). Data points represent the mean ± standard deviation of the mean.

that peptide−membrane interactions are more critical at pH 7.37-38 Thus, we examined the
influence of Zn(II) on the membrane interaction of ClavA under both neutral and acidic
pH conditions. The insertion depth profiles of the α-carbon, side chains, and Zn(II) were
analyzed (Figures S2.15−S2.26). At both pH values, we observed that throughout the
simulation, the C-terminal region of ClavA interacts more consistently and has longer
association times with the membrane than the N-terminal region, when Zn(II) was bound.
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In the systems where ClavA has the least positive charge [P7(−)], the peptide approaches
the membrane in a fashion where the N-terminal region initially interacts with the
membrane and the C-terminal region floats in solution (Figure 2.6A). With Zn(II) bound at
pH 7, visual inspection of the trajectories shows that the N-terminal region still associates
with the membrane, but the C-terminal region has increased interactions with the
membrane (Figure 2.6B). The snapshots for the initial approach in all trials of all systems
are shown in Figures S2.27−S2.30.
Binding of ClavA segments was further quantified by analyzing the number of lipid
contacts made by the C-terminal and N-terminal regions for the first 100 ns during the
longest binding event of each terminal region. This approach does not inform on how long
the regions remain bound, but it provides information on the frequency and amount of
contacts. We designated the first eight residues (VFQFLGKI) as the N-terminal region
and the last eight residues (VHGFSHVF) as the C-terminal region. Each region contains
two Phe residues and can carry up to a +2 charge, depending on the pH. A residue
contact is considered to be formed when the side chain COM is located within 4 Å of the
COM of an upper leaflet phosphate or when the side chain COM is between the
phosphates of both leaflets. To evaluate whether there is a preferential interaction of one
of the regions, differences in the number of N-terminal contacts and C-terminal contacts
were calculated between different simulation conditions (Figure 2.7). At pH 7, binding of
Zn(II) via H17 and H21 significantly increased the number of C-terminal contacts,
accompanied by a decrease in the N-terminal contacts, indicating that Zn(II) biases the
C-terminal region toward the membrane and keeps it from unbinding. Visual observations
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Figure 2.6. Snapshots of the peptide in the (A) absence or (B) presence of Zn(II), when the N-terminal or
C-terminal approaches the model membrane. The snapshots are taken from the longest binding event of
one representative trajectory.

from the trajectories indicate that the decrease in interaction of the N- terminal region
does not completely prevent this region from associating with the membrane. The total
number of contacts between the two systems at pH 7 is not significantly different. This
implies that the peptide maintains its affinity with the membrane during the initial approach
by decreasing the N-terminal−membrane interactions, whereas Zn(II) increases the Cterminal−membrane interactions. Interestingly, binding Zn(II) at pH 5 did not display any
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significant difference in the individual N-terminal and C-terminal contacts, but the total

Figure 2.7. Membrane contact analysis. There are significantly greater number of C-terminal region
contacts than the number of N-terminal region contacts when Zn(II) is present at pH 7. The bars represent
the average of three trials ± the standard error of the mean. Welch’s t-test: *p < 0.05.

number of contacts significantly decreased. This further supports that the observed
increased contacts at pH 7 is due to the stronger electrostatic interactions attributed to
the presence of bound Zn(II). At pH 5, the C-terminal region has a net charge of +2,
regardless of the presence of Zn(II) (Chart 2.1). Another interesting observation is that
when the overall charge of the peptide is increased either by lowering the pH or binding
Zn(II), we consistently observe a significant increase in the C-terminal contacts and
decrease in the N-terminal contacts.
We also employed survival analysis to further confirm the preferential interaction
of the C-terminal region. In this analysis, each binding incident was treated as an event,
and the temporal length of each binding event was measured. The probability of the
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bound region to unbind was defined as the survival probability. This was plotted against
the temporal length of the binding events. As a complement to the first approach, survival
analysis does not give complete information on how frequent the contacts are, but rather
analyzes the length of each binding event before the region unbinds.
At pH 7 when Zn(II) is present, the probability of having a long binding event (>50
ns) for the C-terminal region was significantly larger than for the N-terminal region (Figure
2.8A, right). This was not observed for the systems at pH 5 (Figure S2.31). In comparison,
the binding times of the two terminal regions are not significantly different when Zn(II) is
absent (Figure 2.8A, left). On examining the C-terminal regions, we observed a significant
difference between the binding times when Zn(II) is absent and when Zn(II) is present
(Figure 2.8B).
We went on to examine the preference for ClavA to interact with the different lipids
in our model membrane. Increased positive charge of the peptide should lead to an
increased preference of some residues to interact with anionic POPG lipids. We
calculated the average ratio of POPE−residue interactions to POPG−residue interactions.
One residue−lipid interaction (whether POPE or POPG) is defined as when the region of
interest is located within 4 Å of the upper leaflet phosphates along the bilayer normal.
This criterion was set because the tails are chemically identical between POPE and
POPG, and therefore there should not be any specificity of interactions with the tails. The
bulk ratio of POPE/POPG lipids in the bilayer is 4:1, therefore any ratio below that will
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Figure 2.8. Survival probability analysis of (A) the binding times between the N-terminal region and Cterminal region for ClavA (left) (χ2 < 3.84) and ClavA−Zn(II) (right) (χ2 > 3.84), and (B) the binding times
of the C-terminal region when Zn(II) is present and when Zn(II) is absent (χ 2 > 3.84). Log-rank test: χ2 >
3.84 indicates a significant difference between the survival probabilities of the two samples.

indicate a preference for POPG, whereas any ratio above that will indicate a preference
for POPE. In our simulations, there are two scenarios where the charge of the peptide is
increased: (1) decreasing the pH and (2) binding of Zn(II) (Chart 2.1). Upon binding Zn(II)
at pH 7, there is a drastic shift from POPE preference to POPG preference from Val16 to
His21 (Figure 2.9A), where Zn(II) is locally bound, and this is attributed to the increase in
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the positive charge brought by Zn(II). On the other hand, this was not observed at pH 5.
Instead, all C-terminal residues except His17 retained their preference to POPE (Figure
2.9B). At pH 5 without Zn(II), His17 and His21 are both positively charged, and binding
Zn(II) will not increase the positive charge because these His residues will be
deprotonated to accommodate Zn(II) binding. The lipid preferences of each residue and
Zn(II) in the four different systems are shown in Figure S2.32.
Moreover, we observed that at pH 5, most residues in the N-terminal region (Gln3
to Ile8) have preference for POPG, peaking at Gly6 (Figure 2.9B). This is because His10
and His11 become protonated at pH 5, effectively increasing POPG interactions toward
the N-terminal region. This is also observed at pH 5 with Zn(II), but the preference is lower
in magnitude and it peaks at Ile8. We also compared whether Zn(II) is the preference of
ClavA to interact with POPE or with POPG at the two pH values. Zn(II) was observed to
have more interactions with POPG at pH 7, whereas there are more favorable interactions
with POPE at pH 5 (Figure 2.9C). This does not indicate that Zn(II) changed its
preferential interaction from POPG to POPE as pH is decreased. Our hypothesis is that
the two additional protonated His residues at positions 10 and 11 elicit more electrostatic
interactions with POPG at pH 5 than with Zn(II). Zn(II) will still want to interact with POPG,
but it will have to compete with the protonated residues in terms of binding to POPG, and
there will be less available POPG for Zn(II) to interact with. To support the hypothesis, we
calculated the probability density of POPG lipids around each residue at both pH levels
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Figure 2.9. Comparison between different systems: (A) P7(−) vs P7(+), (B) P5(−) vs P5(+), and (C) P7(+)
vs P5(+) showing the ratio of POPE interactions to POPG interactions of each residue normalized against
the bulk ratio of POPE/POPG (4:1) in the model membrane. The bars represent the average of three trials
± the standard error of the mean. The amino acid sequence of ClavA is written below the x-axis, with blue
and red letters indicating nonpolar and polar residues, respectively.

averaged over the last 400 ns of the simulation and all trials. This analysis shows the
probability of having one POPG lipid within 4 Å of each residue. To calculate the
probability for each residue, the total number of POPG lipids within 4 Å was determined
and divided by 400 because the total analysis time is 400 ns. A probability of 1 means
that, on average, one POPG is around the residue every nanosecond, and a probability
of 12 means that all POPGs in the leaflet are found around a given residue every
nanosecond. The time course of the number of POPG lipids around each residue during
the full simulation is shown in Figure S2.33. At pH 7, large densities of POPG were
present around residues Gly18 to Phe23, which spans the C-terminal region of the
peptide (Figure 2.10). Moreover, there is a large density of POPG around Zn(II) at pH 7.
At pH 5, the POPG densities in the C-terminal region decreased drastically, whereas
some residues in the N-terminal region (Val1, Gln3, Gly6, and Lys7) and on the central
region (Val12 to Asn14) increased in POPG density. The implication is that the protonated
His residues at positions 10 and 11 significantly contributed to the increase of anionic
POPG lipid interactions toward the N-terminal region. The individual density heat maps
of POPG lipids around each residue are shown in Figures S2.34 and S2.35.
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Figure 2.10. Probability density of POPG lipids around each residue of ClavA. Residue number 24
represents Zn(II). A high probability of POPG lipids surrounding Gly18 to Phe23 and Zn(II) at pH 7 is
observed. The probability decreased at pH 5 with an increase in the probability around the N-terminal
residues.

Effect of Zn(II) on Membrane Properties
Zn(II) also interacts with the membrane by coordinating with the negatively
charged head group phosphates when the peptide is bound to the lipid. Hence, we were
interested in how Zn(II) can modify different properties of the membrane, including
membrane thickness, area per lipid, and area compressibility modulus, when the Zn(II)
ions are only interacting with one leaflet of the bilayer (see Methods). At Zn(II)/lipid ratios
of 1:120 to 1:30, there were no significant changes in any of the membrane properties
(Figure 2.11). Starting at a ratio of 1:15, the membrane thickness increased and the area
per lipid decreased. This indicates that the membrane started to lengthen along the
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membrane normal and compress laterally. Meanwhile, the compressibility modulus
decreased dramatically at a ratio of 1:15 and above, indicating that the membrane can
more easily undergo in-plane deformations because of the increased fluctuations in the
area per lipid. To validate whether the observed trend is dependent on the time scale of
analysis, we have plotted the different Ka values calculated using different analysis
windows (Figure S2.36). The absolute values of Ka show some variation, but a significant
change in the properties is always observed at Zn(II)/lipid ratios of 1:15 and higher. We
also conducted three simulations each for the system with no Zn(II) and the system with
a 1:7.5 Zn(II)/lipid ratio, where the lateral pressure is set to different values to produce a
nonzero surface tension on the lipid bilayer. This is an alternative method of calculating
the area compressibility modulus by fitting the changes in the area per lipid (A) against
the surface tension (γ), according to the following equation:

𝐾𝑎 = 𝐴 (2

𝑑𝛾
)
𝑑𝐴

The simulations were run for 100 ns, and only the last 60 ns were considered for data
analysis (Figure S2.37A). We have obtained Ka values [151.92 mN/m for no Zn(II) and
137.51 mN/m for 1:7.5 Zn(II)/lipid] that are different from our previous methodology, but
we still observe a significant decrease in the area compressibility modulus at the highest
number of Zn(II) ions interacting with the membrane (Figure S2.37B).
We also examined how the membrane properties were affected by ClavA [with or without
Zn(II)]. Interestingly, we observe an opposite effect in the membrane thickness and the
area per lipid for peptide−membrane simulations in both Zn(II)-absent and Zn(II)restrained systems. Interaction of ClavA with the membrane creates an additional surface
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area in the bilayer plane leading to increased area per lipid and membrane thinning
(Figure 2.11). The compressibility modulus of the membranes in ClavA systems without

Figure 2.11. (Left) Effect of Zn(II) concentration on the membrane thickness, area per lipid, and area
compressibility modulus of the gram-negative bacterial membrane model. (Right) Effect of peptide
interactions under different system conditions: pH 7 or 5, Zn(II) absent, Zn(II) restrained to His17 and
His21, or 32 Zn(II) ions unrestrained. Significant changes in the membrane properties were observed at
Zn(II) concentrations at or above 1:15 Zn(II)/lipid ratio.

Zn(II) decreased significantly, similar to the Zn(II)−membrane systems at ratios of 1:15
and 1:7.5. Binding Zn(II) to ClavA neutralizes this effect, restoring the compressibility
modulus to the value observed in membrane-only systems. An additional system was
considered with ClavA and 32 free Zn(II) ions [1:7.5 Zn(II)/ lipid ratio]. We ran three trials
of this system, and the effects on the membrane were similar to the Zn(II)−membrane
system with a 1:7.5 Zn(II)/lipid ratio.
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Discussion
There are three main effects of Zn(II) that were observed from this simulation
study: (i) Zn(II) stabilizes helical conformations in the C-terminal region by coordinating
to His residues in the HXXXH motif and acts as a structural staple; (ii) Zn(II) influences
the behavior of the C-terminal interactions with the gram-negative bacterial membrane
model; and (iii) both peptide and Zn(II) cause changes to structural and mechanical
properties of the bilayer, causing lower energy cost for in-plane stretching deformations.
There is a wide variety of studies done on peptide stapling, including those that use allhydrocarbon molecules as staples.39-40 These staples decrease the conformational space
available for the peptide backbone, restrict the peptide to its helical conformation, and in
effect, stabilize the helicity of the peptides. There should be a balance between
hydrophilic and hydrophobic residues for an AMP to penetrate the cell membrane, as
electrostatic interactions are crucial in approaching the polar head groups while
hydrophobic effects are important when interacting and crossing the hydrophobic core of
the bilayer. Cationic and amphipathic peptides, such as ClavA, are advantageous for cell
entry as they have an amphipathic character. However, this amphipathic character is
most pronounced when the peptide is in an ordered secondary structure, such as an αhelix. ClavA is a short, disordered peptide in solution, and it can be inferred that a helical
conformation will be marginally stable (or unstable) because of the loss of configurational
entropy upon folding. In this respect, Zn(II) can act to reduce the configurational space in
the unfolded state and hence reduce the entropy loss upon folding. We believe this effect
will stabilize an α-helical segment in the C-terminal region in the presence of the
membrane. The stabilization of the helix facilitates membrane penetration by the
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hydrophobic effect when ordered waters are released into the bulk when the peptide
hydrophobic face buries into the bilayer.
When ClavA is inserted into the bilayer, the hydrophobic environment of the
membrane was found to stabilize the overall α-helical structure of ClavA. The backbones
atoms of Val1 and Phe23 of ClavA interacted through weak hydrogen bonds with the
water molecules present at the surface of the membrane (Figure S2.38). Superposition
of ClavA and ClavA− Zn(II) showed that the two structures were quite similar with an
overall rmsd of 3.05 Å. However, His17 in the Zn(II)-free form was flipped away from the
position it adopts in the Zn(II)-bound system, whereas His21 maintained the same
orientation in both forms.
The importance of the C-terminal region of ClavA is also highlighted by the
observation that binding Zn(II) resulted in a longer and more favorable interaction of the
C-terminal region with the lipids, as compared to that of the N-terminal region. Moreover,
the C-terminal region exhibited a shift in preference to POPG interactions when it is Zn(II)bound at pH 7. On the other hand, at pH 5, the Zn(II)-bound C-terminal region retained
its interaction with POPE because two protonated His residues, His10 and His11,
compete with Zn(II) in interacting with POPG. We hypothesize that this will consequently
pull POPG toward the N-terminal region and away from the C-terminal region, leaving
Zn(II) to interact with POPE. All these observations show the importance of the charge
state of both the peptide and the membrane.
The initial contact of metalloAMP to the membrane is due to the electrostatic
interactions of the anionic lipids in the model membrane and the two components of the
metalloAMP: (i) positively charged residues, such as histidines (at pH 5) and lysines (at
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pH 7 and 5) or (ii) the metal cation bound to the peptide. In this case, we propose the
metal cation shifting the equilibrium toward the folded state, which in turn favors
interactions with the membrane because of the amphipathicity of the helical peptide.
However, we hypothesize that the metal ion should not bind too tightly to the metalloAMP,
as the metal ion will not be able to efficiently translocate across the membrane because
of highly unfavorable interactions with the lipid tails and favorable interactions with the
lipid head groups. Enhancement in the binding of ClavA was also observed in the
simulations through the survival analysis, which showed longer binding times for the
Zn(II)-bound C-terminal region as compared to ClavA without Zn(II).
In studying the peptide−membrane interactions of cationic metalloAMPs using
classical MD simulations, it is informative to examine the local environment of the
metalloAMP as it interacts with the model membrane. We see that the Phe residues can
readily cross the polar head group region of the bilayer and insert deeply into the
hydrophobic region of the bilayer. A previous study on ClavA highlighted the importance
of Phe residues by providing balanced hydrophobicity, membrane affinity, and
conformational flexibility of ClavA.36 Together with our findings, this gives us insight on
the crucial role of Phe residues in the antimicrobial activity of ClavA and why these
residues are highly conserved in clavanins (Figure S2.39). A potential future direction
would be to investigate ClavA mutants involving Phe mutations to other hydrophobic
residues, such as isoleucine or tryptophan, and evaluate the effect on membrane binding
and insertion. Second, we would like to note that we have not observed the ClavA models
to be completely buried in the membrane. Charged residues are important for membrane
binding, but it is believed that most charged residues will lose their charge as they enter
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the low dielectric environment of the membrane interior.41-42 However, this feature cannot
be captured in classical MD simulations because of the fixed charge model of the force
field. Fluctuating charge models, such as polarizable force fields for proteins and lipids or
constant pH MD simulations,43-46 can in principle be employed to overcome this limitation.
In previous studies, the interaction of Zn(II) with the phospholipid 1-palmitoyl-2oleoyl-sn-3-glycero-phosphocholine (POPC) was shown to create Zn(II) bridges between
adjacent lipid molecules that stabilize the gel phase of the bilayer. 47 This bridge causes
the POPC membrane to be less laterally compressible. 47 Interestingly, our simulations
show an opposite behavior. The area compressibility modulus of the membrane model
decreases starting at a Zn(II)/lipid ratio of 1:15, which indicates that the membranes can
be deformed easier. This could be due to the differences in the membrane composition,
as the larger size of choline head groups relative to the glycerol and ethanolamine could
create a different mechanical response. On the other hand, our results agree with an
experimental study that shows an increase in the membrane thickness in 1,2-dipalmitoylsn-glycero-3-phosphocholine (DPPC).48 It has been observed that both Ca(II) and Zn(II)
bindings result in membrane thickening, but a critical concentration of Zn(II) swells the
DPPC membrane to a maximum thickness, with no further thickening at concentrations
higher than the critical concentration. 48 Higher concentration of Ca(II) with respect to
DPPC, on the other hand, results in bilayer thinning.48 Another interesting observation is
the ability of ClavA to decrease the area compressibility modulus of the membrane model
comparable to what is observed at high Zn(II) concentrations [1:15 Zn(II)/lipid ratio] but
with decreased membrane thickness and increased area per lipid. This could be a
contributing factor to the membrane penetration of the peptide as it attacks its target.
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Oddly, binding Zn(II) inhibits this effect, and this opens up a further area of investigation
as to how this happens. A possible implication of this phenomenon is that once Zn(II) has
served its role of pulling the peptide closer to the membrane, it will unbind from the peptide
and interact with the anionic lipids, and this will prevent the membrane from transitioning
into a less compressible state.
In this study, we have employed equilibrium constant temperature simulations,
performed in replicates, to statistically analyze different effects on the peptide
conformation and membrane interactions. Because of the time scale limitations in
standard MD, we were unable to observe Zn(II)-induced spontaneous helical formation in
the C-terminal region. In MD simulations, significant formation of secondary structures is
well-observed on a time scale of microseconds to milliseconds, which is beyond the time
scales simulated in the current study.11,
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There are various simulation approaches,

which can be employed to access longer time scale phenomena from shorter simulation
lengths. These approaches, known collectively as enhanced sampling methods,
accelerate the sampling through temperature-based methods (e.g., replica exchange) by
applying biases along specific variables of the system (e.g., umbrella sampling,
metadynamics) or by stitching together independent short simulations that sample
different regions of phase space (e.g., weighted ensemble, Markov state models).50-54 In
future studies, we aim to further examine ClavA folding through an enhanced sampling
approach to assess thermodynamics quantities, which can only be accurately calculated
from converged equilibrium probabilities. Another limitation in the current study is we were
unable to observe the spontaneous formation of Zn(II)−histidine complexes when we
expose ClavA to unrestrained Zn(II) ions. CHARMM36 is a standard unpolarized force
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field that models charges as being fixed. Therefore, our current system cannot accurately
depict the polarization effects of the metal center Zn(II) to its potential histidine ligands.74
To explore spontaneous binding of Zn(II) to ClavA, force fields such as the Extended Zinc
AMBER Force Field or polarizable force fields, such as AMOEBA, are likely to provide
increased accuracy in modeling the ClavA−Zn(II) complex.55-58
Conclusions
We present a domino-effect model on how Zn(II) facilitates ClavA membrane
interactions that could potentially contribute in the enhancement of antimicrobial activity
(Scheme 2.1). First, Zn(II) binding to ClavA increases the net positive charge in the Cterminal region of the peptide, driving the peptide closer to the membrane, increasing the
effective concentration, and possibly causing peptide localization on the cell membrane,
as observed experimentally.3 An alternative possibility is that Zn(II) will first bind to the
membrane via electrostatic interactions with the anionic lipids, which could then enhance
the affinity of the C-terminal region of ClavA to the membrane. However, the peptide
interactions with a Zn(II)bound membrane were not explored in the current study. Once
ClavA is in contact with the membrane, the Phe residues start to penetrate the membrane.
ClavA will then have an increased probability of forming an α-helical conformation as the
peptide positions its polar residues along the polar head groups and its nonpolar residues
along the nonpolar lipid tails. Zn(II) can then act to restrict conformational sampling and
favor folding as well as act as a peptide staple, stabilizing the helical conformation once
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Scheme 2.1. Proposed Domino-Effect Model for the Role of Zn(II) in the Helical Stability, the Enhanced
Membrane Interaction of the C-Terminal Region, and the Role of Zn(II) in Greater Bilayer Deformability

formed. Once stable, Zn(II) can unbind from the peptide, interact with the membrane, and
cause an easier lateral deformation of the membrane. This will increase the probability of
having lipids spaced out away from each other, such that ClavA can insert itself into the
bilayer and transition to a transmembrane state. We do not suggest that all AMPs can
take advantage of the lateral membrane-deforming effect brought by Zn(II) binding to the
membrane. For example, the antimicrobial activity of magainin 2, clavanin C, and the
anionic peptide maximin H5 do not get potentiated in the presence of Zn(II). 3,
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In

contrast, the AMP kappacin and an anionic hexapeptide from the human amniotic fluid
potentiate their activities in the presence of Zn(II). 60-61 Interestingly, all AMPs we
identified, which have enhanced antimicrobial activity in the presence of Zn(II), contain
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the HXXXH motif, except for the ovine pulmonary surfactant-associated anionic peptides
(Figure S2.40).
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Chapter 3

Exploring Translocation Pathways of Clavanin A across an E. coli Outer
Membrane Model through Enhanced Sampling Techniques
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Introduction
One of the roles of biological cell membranes is to separate the components of a
cell from its external environment and to compartmentalize organelles, such as
mitochondria and the nucleus, in eukaryotic cells.1-4 They act as effective barriers to
protect the cell from extracellular components that are potentially harmful or not needed
by the cell. The compartmentalization of specific functions in eukaryotic cells are possible
through having different organelles, which have specific membrane composition for its
function.2, 4-5 Substances can be transported into and out of the cells either by passive
transport across the cell membrane, or by active transport through membrane proteins
embedded within the membrane. Cell membranes are predominantly made up of lipid
molecules in a bilayer structure, with different lipid compositions varying by membrane
type, by leaflet and across cell types. For example, the plasma membrane in eukaryotic
cells are composed mainly of saturated lipids, sphingomyelins, and glycolipids in the outer
leaflet, while their inner leaflet is composed mainly of unsaturated charged lipids such as
phosphatidylserine.2,

6

Gram-negative bacterial cells have inner and outer cell

membranes that are separated by the periplasmic space. 7-8 The outer leaflet of the outer
membrane is mainly composed of glycolipids, while the inner leaflet is composed of
phospholipids.7-8 Gram-positive bacterial cells have a cell wall containing a peptidoglycan
layer with a thickness of about 40 to 80 nm, much larger than that in Gram-negative
bacteria.9 Their cell wall contains teichoic acid that can be conjugated to the plasma
membrane through a glycolipid anchor.9 Both have plasma membrane (also known as
the inner membrane in Gram-negative bacteria) which separates the periplasmic space
from

the

cytosol.9

They

both

contain
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phosphatidylethanolamine

(PE)

and

phosphatidylglycerol (PG), with higher proportion of PG in Gram-positive bacteria and PE
in Gram-negative bacteria.9
In Chapter 2, we have demonstrated the effect of varying the pH and binding Zn 2+
on the structure of ClavA and its interaction with a simplified model of an E. coli outer
membrane. The initial attraction of the cationic ClavA to the anionic model membrane
was shown to be enhanced by making the net charge of ClavA to be more positive. This
was done by protonating the His residues, which may happen biologically when the pH
of the local environment is decreased from 7 to 5. Also, binding Zn2+ to the HXXXH motif
of ClavA can increase the positive charge of ClavA. In all simulations presented in the
previous chapter, none of those were able to show that ClavA can translocate the lipid
bilayer in the timescale we simulated (500 ns). Thus, we became interested to evaluate
the behavior of ClavA as it translocates at different protonation states. Furthermore, we
wanted to use a more complex model of an E. coli outer membrane as this was not yet
explored in any of the AMP literature.
As we have not observed any translocation events from the 500 ns-long unbiased
MD simulations, we can assume this as a rare event. In MD simulations, studying these
rare events is possible by using methods which bias the system along a particular variable
or set of variables such as steered MD, umbrella sampling, 10-11 metadynamics,12-14 and
replica exchange simulations.15-17 In this chapter, we employed a combination of steered
MD and metadynamics to generate trajectories for the translocation of ClavA across the
lipid bilayer. Selected pathways were subjected to Hamiltonian replica exchange (HREX)
simulations to extensively sample the pathway and calculate the free energy of ClavA
translocation at different protonation states. As we obtained large free energy values,
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which would make the translocation event physiologically improbable, we proceeded by
looking for oligomers at the different protonation states, and generate translocation
pathways for these oligomers using metadynamics and steered MD simulations.
Methodology
Simulation Models. The ClavA simulations were initiated from the helical
conformation determined by solution-state nuclear magnetic resonance (NMR) PDB ID:
6C41,18 in which an α-helical segment was observed from residues Phe2 to Val22. This
structure was obtained in 35% 2,2,2-trifluoroethanol (TFE)-d3, a solvent which provides a
low dielectric constant similar to a membrane, 10% D2O, and 55% buffer at pH 4.3.
Chemical modifications to the peptide were performed using CHARMM-GUI,19-21 which
included C-terminal amidation and protonation of histidines (His) in systems modeling a
pH 5 environment (Chart 3.1). In the pH 5 environment, two different models were
generated. In the first model (p5_4H), all His residues were protonated, and in the second
model (p5_2H), only His17 and His21 were protonated. The p5_2H model was generated
to explore the possibility of an α-helical ClavA in a transmembrane state. Here, the central
histidines, His10 and His11, will be situated in the hydrophobic region of the lipid bilayer.
Thus, it is more favorable for these His residues to be deprotonated.
The peptide models were solvated with the TIP3P water model22 and 150 mM
NaCl. The peptide models were also simulated in the presence of a more realistic Gramnegative bacterial membrane model,7-8 different from the model used in Chapter 2. In this
more complex model, the outer leaflet consisted of 33 lipid A molecules (Figure 3.1) while
the inner leaflet consisted of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine
(POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3phospho-(1′-rac-glycerol) (POPG), and 1,1074

palmitoyl-2,20-vacenoyl cardiolipin (PVCL) lipids (Figure 3.1). The inner leaflet contained
100 lipids with a ratio of 80:15:5 POPE/POPG/PVCL. The peptide models were initially

Figure 3.1. Structures of the lipid molecules used in the simulations.
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placed approximately 3 nm above the membrane outer leaflet. The peptide−membrane
system was generated by using the CHARMM-GUI server.19-21
Energy minimization and equilibration steps were performed according to the
CHARMM-GUI protocol, employing the steepest descent minimization for 500 steps and
three successive canonical ensemble equilibrations for 25 ps (1 fs timestep) followed by
three successive isothermal−isobaric ensemble equilibrations for 50 ps (2 fs timestep).
Semi-isotropic pressure coupling was used to generate a zero surface tension ensemble
using the Berendsen barostat. During the equilibration steps, positional restraints on
protein heavy atoms and lipid phosphorus atoms were employed. Dihedral restraints were
placed on the lipid glycerol and tail moieties around the unsaturated bond. The force
constants for these restraints were gradually decreased after each equilibration step.
Unbiased isothermal-isobaric MD simulations were run for about 600 ns each using a
timestep of 2 fs and temperature of 300 K. Temperature was maintained using a
Nose−Hoover thermostat23-24 with a coupling time constant of 1 ps. A semi-isotropic
pressure coupling scheme was implemented using the Parrinello−Rahman barostat25 with
a coupling constant of 5 ps. The lipid bilayer compressibility was set to 4.5 × 10−5 bar −1,
and the reference pressure in the bilayer plane (XY) and bilayer normal (Z) was set to 1
bar. Van der Waals interactions were cut off at 1.2 nm, with the interactions being modified
using the force-switch method between 1.0 and 1.2 nm. Long-range electrostatic
interactions were calculated using the particle mesh Ewald method, with a real-space
cutoff of 1.2 nm.
The unbiased MD simulations were performed using GROMACS 202026 program
and the CHARMM36m27 force field. The metadynamics and HREX simulations were
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performed using GROMACS 201928 program. The trajectories were visually analyzed
using VMD,29 and further quantitative analyses were performed using a combination of
GROMACS tools, MDTraj,30 and in-house Python scripts.
Results and Discussion
Peptide Tilt Angle as Collective Variable for Metadynamics and HREX
Chapter 2 highlighted the role of the C-terminal region in the initial attraction of
ClavA to the lipid bilayer. Building from this idea, we hypothesize that as ClavA inserts
into the bilayer, its C-terminal region will insert deeper into the bilayer, resulting in a
transmembrane (TM) state wherein the N-terminal region is interacting with the outer
leaflet headgroups while the C-terminal region is interacting with the inner leaflet
headgroups. Thus, we initiated metadynamics simulations from the described
transmembrane state of helical ClavA. To explore pathways from transmembrane state
to surface-bound (SB) state, we defined a tilt angle collective variable. In this CV, there
is a vector that points from the center-of-mass (COM) of the first five N-terminal residues
to the COM of the last five C-terminal residues. There is another vector that points to the
negative z-axis, as defined by the membrane normal of the system. The angle between
these two vectors is the CV we biased. When the angle is equal to 0°, this indicates that
ClavA is at TM state and when this angle is equal to 90°, this indicates that ClavA is at
SB state (Figure 3.2). There are two assumptions that have to be made with this definition:
ClavA remains completely helical throughout the simulation, and at an angle close or
equal to 90°, almost all or all residues are in the headgroup region of either leaflets. The
pathways from TM state to SB state were successfully generated (Figure 3.3, top) when
the following metadynamics parameters are used: sigma = 0.2 rad, height = 2 kJ/mol,
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Figure 3.2. Definition of tilt angle as the collective variable. The vector pointing towards the negative of
the membrane normal axis is drawn in black. The vector pointing from the N-terminus to C-terminus of
ClavA is drawn in red.

gaussian deposition frequency = every 1 ps. Ten independent simulations were run for
each system. To have a pathway where ClavA transitions from TM to SB state, the tilt
angle in the trajectories should cover 0° to 90°. However, in some simulations, the tilt
angle started going back down even before it reaches the tilt angle of 90°. These
simulations were not considered for further refinement using HREX. There are
simulations where the tilt angle went as far as 180°, indicating that the ClavA flipped from
the N-terminus interacting with the outer leaflet lipid headgroups to an orientation with the
C-terminus interacting with the outer leaflet lipid headgroups. The trajectory for each
system that was chosen for the HREX simulations is that which has the lowest free energy

78

Figure 3.3. (top) Time evolution of the ClavA tilt angle explored with metadynamics simulations. Tilt angle of 0° indicates transmembrane state
and tilt angle of 90° indicates surface-bound state. (bottom) Free energy surface obtained from metadynamics. Chosen trajectories for HREX are
highlighted in red.
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surface among those trajectories that covered tilt angles from 0° to 90° (Figure 3.3,
bottom). For the HREX simulations, windows were selected such that the harmonic
restraints are centered from 3° to 90°, in a total of 30 windows. The free energy surface
for each system was constructed by performing the weighted histogram analysis method
(WHAM) (Figure 3.4). At pH 7, there is an extended energy basin from 0° to 30° and the
free energy increases as the peptide goes surface-bound. The energy minimum for the
systems at pH 5 are centered at around 30°, indicating that ClavA prefers to be in a tilted
configuration rather than TM or SB configuration. From the tilted conformation, it requires
20 to 30 kJ mol-1 of energy to transition to TM state, but it requires greater energy to
transition to SB state. The p5 and p5_2H systems require 95 kJ mol -1 and 65 kJ mol-1,
respectively, for this transition. The lower ΔG requirement for the tilted conformation to
either SB or TM conformation at p5_2H can be attributed to the deprotonation of the two
central His residues. As ClavA transitions from TM to SB, these residues are situated in
the hydrophobic region of the lipid bilayer, which will become less energetic. To validate
these results, we tried to generate pathways from SB state to TM state, opposite the initial
pathways generated. As free energy is a state function, for a reversible process, the ΔG
that will be obtained from the two opposite pathways must be negative of each other.
However, we were not able to generate SB to TM pathways using the same
metadynamics parameters. When the peptide is initiated such that it is bound to the
surface of the outer leaflet, it is possible for the peptide to move towards the solvent,
instead of inserting into the bilayer. This makes it more difficult to generate SB to TM
pathways. Thus, we started exploring a more direct CV which will explore the distance of
the peptide to the inner leaflet phosphates. In the following set of simulations, we have
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Figure 3.4. Free energy profile of the ClavA systems generated from HREX simulation using tilt angle as
CV.

also added an imaginary wall above the outer leaflet parallel to membrane surface. This
has a harmonic potential that exerts force towards the peptide as the peptide move
towards it, preventing the peptide from interacting with the inner leaflet by crossing the
periodic boundary.
COM Distance as Collective Variable for Metadynamics and HREX
Due to our inability to produce SB to TM pathways using tilt angle as collective
variable, we have chosen a new collective variable to simulate the translocation of ClavA
from the extracellular side of an E. coli outer membrane. This CV is defined as the
distance along the z-axis between the COM of the peptide and the COM of the inner
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leaflet phosphate groups. In all systems except p5_2H, ClavA was initially located above
the outer leaflet headgroups. In p5_2H, the ClavA was initially at the outer leaflet
headgroup region after equilibration. All 30 trials of the metadynamics simulations allowed
the peptide to reach the inner leaflet phosphates in less than 10 ns (Figure 3.5, top), which
is much faster than the simulation times in generating pathways using tilt angle as CV.
This is due to the much larger Gaussian hill heights used in running these simulations, as
compared to the previous methodology. We have increased the hill height from from 2
kJ/mol to 100 kJ/mol, , as we cannot see ClavA enter the lipid bilayer using a hill height
of 2 kJ/mol. Using a larger hill height could lead to large bias energies that will greatly
perturb the membrane. Indeed, we have seen that the outer leaflet lipids are brought into
the inner leaflet by the ClavA. In choosing the pathway to be used for HREX, we have
monitored how the tilt angle changes with the distance between COMs and simulation
time. To have a valid comparison between systems, we have chosen the pathways which
have the closest final tilt angle as the ClavA crosses the lipid bilayer (Figure 3.5, bottom).
HREX simulations were then conducted from these pathways and free energy profiles
were constructed (Figure 3.6). In all systems, ClavA requires large energy to cross the
lipid bilayer. At the p7 system, ClavA required 700 kJ mol-1, followed by p5 and p5_2H
systems, which required 550 kJ mol-1 and 350 kJ mol-1, respectively. These large energies
can be attributed to the instability of the outer leaflet headgroups as it gets pulled by
ClavA, leading to their unfavorable interaction with the hydrophobic region of the bilayer.
We hypothesize that either ClavA cannot directly cross the membrane as a monomer, or
it is brought inside the cell via transport membrane proteins. Interestingly, the p5_2H
system has an energy minimum at around 3.5 Å, suggesting that the ClavA in this
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Figure 3.5. (top) Time evolution of the ClavA–lower phosphate Z-distance in the metadynamics
simulations. The chosen trajectory for each system is highlighted in red. (bottom) Tilt angle and ClavA–
lower phosphate Z-distance of the chosen trajectory through time (red to blue)

protonation state prefers to reside in the outer leaflet headgroups of the bilayer. This was
also observed during equilibration of the p5_2H system. ClavA preferred to stay at the
headgroup region, as seen in its initial location before running metadynamics for this
system.
Generating Pathways using Steered MD
Due to the large free energy changes observed from the previous metadynamics
simulations, we attempted a different methodology to generate ClavA translocation
pathways. This time, we have run an unbiased simulation of the E. coli outer membrane
model without ClavA until the area per lipid of the bilayer equilibrates (Figure 3.7). This
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Figure 3.6. Free energy profile of the ClavA systems generated from HREX simulation using COM
distance along the z-axis between ClavA and inner leaflet phosphate groups as CV.

allows for the membrane to relax before the peptide inserts into it. The previous
simulations were initiated from membranes having equilibration times of 1.875 ns. With
this short amount of equilibration time, the membrane may not be completely relaxed,
contributing to the large free energy changes observed previously. The ClavA was placed
about 2 nm above the membrane, and metadynamics simulations were run using the
COM distance described above as CV (Figure 3.8). However, ClavA never got past the
outer leaflet lipid headgroups, even after using the same parameters with large hill height.
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Figure 3.7. Equilibration of the E.coli outer membrane model by monitoring the area per lipid through
time.

Figure 3.8. Trajectories of the metadynamics simulations as ClavA inserts into an equilibrated model
membrane of an E. coli outer membrane

It may be noticed that there are some trajectories where the peptide oscillated at around
6.5 nm (2.5 nm above the membrane). This is due to the presence of an imaginary wall
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that was present in the system to avoid the peptide from crossing the periodic boundary
conditions and interacting with the inner leaflet.
To address this problem, we ran steered MD simulations that pulled ClavA towards
the inner leaflet phosphates at a rate of 1 Å per ns using a force constant of 1000 kJ mol1.

Despite the large force constant, we were able to generate trajectories that translocates

the lipid bilayer without greatly perturbing the membrane (Figure 3.9). However, we were

Figure 3.9. (top) Time evolution of the COM distance from the steered MD simulations. (bottom) Snapshots
from the trajectory showing ClavA after crossing the bilayer.

not yet able to construct free energy profiles through HREX simulations due to
equilibration problems in some of the frames that were extracted.
Translocation of Oligomeric ClavA
To test the hypothesis that ClavA requires oligomerization to cross the bilayer, we
ran unbiased MD simulations of the E. coli outer membrane model with six ClavA peptides
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placed randomly 2 nm above the membrane for around 500 ns. We have identified the
largest oligomer from each system using the clustering analysis. The center of each
cluster was extracted and used as the starting structure for metadynamics simulations.
Similar to the COM distance CV used in the previous simulations, the CV that we explored
with the oligomers is the distance along z-axis between the COM of the oligomers and
the COM of the inner leaflet phosphate groups. However, we were not able to successfully
translocate ClavA through metadynamics simulations (Figure 3.10). The oligomers

Figure 3.10. (top) Time evolution of the COM distance from the metadynamics simulations of the
oligomeric ClavA. (bottom) Snapshots from the trajectory showing the bilayer deformation.

induced large curvatures to the bilayer without getting past the outer leaflet headgroups.
Thus, we used steered MD to bias the peptide in crossing the bilayer (Figure 3.11). In all
the resulting trajectories, the oligomers perturbed the membrane by inducing curvature,
but the peptides were able to successfully cross the bilayer. In the p7 and p5_2H systems,
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Figure 3.11. (top) Time evolution of the COM distance from the steered MD simulations of the oligomeric
ClavA. (bottom) Snapshots from the trajectory showing peptides crossing the lipid bilayer.

the peptides crossed as oligomeric unit but it pulled lipids along with it. In the p5 system,
the peptides initially moved together but eventually, the interactions between the peptides
were broken resulting into only one peptide crossing the bilayer.
Conclusion
We were able to use two different MD simulation techniques in generating
pathways that would accelerate the translocation of ClavA across the lipid bilayer. While
these translocation events may easily be observable in real systems, they are considered
as rare events in MD simulations. This emphasizes the significance of being able to use
biased simulation techniques to observe such events, especially in complex model
membranes that represent a more realistic composition of a bacterial membrane. These
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sampling techniques have been used before in simple model membranes, 31-35 but to our
knowledge, this is the first time that these were used in complex model membranes. The
challenges that one may encounter in doing these types of simulations in complex
membranes were seen from our results. In metadynamics, the bias introduced to the
system does not impose directionality along a collective variable, unlike in steered MD
simulations. While this is more favorable because the system is allowed to explore along
the defined collective variable, the system may still get stuck in an energy well. It may still
require longer simulation time or more independent simulations to generate the desired
pathway. Additionally, running independent simulations can produce different pathways
that have the desired initial and final states. The free energy profiles that can be generated
from these pathways can reveal information as to which pathway will be less energetic
and more favorable for the system. However, as seen in Figures 3.3 and 3.4, the energy
profiles generated from the metadynamics and HREX, but using the same system, were
very much different. There are no available experimental data to validate the accuracy or
correctness of the profiles. However, the difference in energy profiles can be attributed to
their difference in sampling times. For example, if the desired pathway was generated
using metadynamics in 10 ns, the sampling time is only 10 ns for the free energy profile
that will be constructed. But in HREX simulations, if the desired pathway will be run for
10 ns, each window must be sampled for 10 ns, resulting to a total sampling time of 10n
ns, where n is the number of windows. This shows the advantage of using HREX
simulations to construct the free energy surface along the chosen collective variable. It
allows other degrees of freedom in the system to equilibrate, cancelling their energetic
contributions. In the free energy surfaces constructed from metadynamics, the calculated
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free energy can be due to other degrees of freedom that were not controlled during the
simulation.
In terms of biological relevance, the results from the study opened more interesting
questions. The hypotheses that was not completely addressed from the results is that
ClavA at pH 5 requires less energy to cross the outer membrane, as it likely acts on an
internal cell target. At pH 7, it will be more difficult for ClavA to cross the membrane; thus,
it will prefer to be in a transmembrane or close to transmembrane state to be able to form
pores. It was initially suggested that ClavA kills via nonspecific pore formation at neutral
pH.36 The large free energy values that were calculated from crossing the lipid bilayers in
all systems suggests that either the peptide cannot cross the bilayer as a single
monomeric unit or that it enters the cell through active transport. In future studies, we will
be evaluating the difference in ΔG of translocating a monomeric ClavA and ΔG of
translocating oligomeric ClavA through HREX simulations to address this.
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Chapter 4

Using Principal Component Analysis to Identify
Mechanisms of Action of Clavanin A
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Introduction
Bacterial cytological profiling (BCP) has become a common and effective approach
in identifying the mechanisms of action (MoA) of antimicrobial and anticancer
compounds.1-4 This is a simpler alternative to traditional assays that are commonly used,
such as macromolecular synthesis assays.2, 5 Another approach is to induce resistance
to the bacterial cells by exposing them to antibiotic molecules, isolating the cells, and
profiling the genes that were expressed at the transcription level. 6-7 BCP has been shown
to accurately predict the MoA of new small molecule antibiotics by comparing their effects
on the different cytological properties to that of commercially available antibiotics with
known MoA.1-3 In this technique, properties of cells such as circularity and number of
nucleoids per cell are measured after treating the cells with antibiotics. Due to the
complexity of having multiple dimensions (or observables), a dimensionality reduction
technique called principal component analysis (PCA) can be done to simplify the amount
of data to two to three dimensions, which can be easily visualized and analyzed.
Over the years, there have been disagreements in the literature on the MoA for
Clavanin A (ClavA). The initial proposal is that it permeabilizes the outer and inner
membranes of Gram-negative bacteria.8-10 At a pH of 7.4, nonspecific pore formation was
observed, and this process is driven by hydrophobic effects. 10 At an acidic pH of 5.5, the
peptide becomes more positively charged due to the protonation of His residues. It is
hypothesized that the peptide starts to interact with membrane ionophores or ATP
synthases, interfering their function to transport small ions.10 Bacteriorhodopsin, for
example, contains negatively charged Asp residues in its active site.11 These anionic
residues can interact with the highly cationic ClavA via electrostatic attraction. Recently,
94

a different MoA was proposed wherein ClavA damages bacterial DNA, as evidenced by
in vitro DNA cleavage assays.12
In this chapter, we showed that applying PCA, in conjunction with BCP, can reveal
the MoA of ClavA at the two different pH levels, providing a clearer picture on how ClavA
kills E. coli. We compared the cytological profiles of E. coli cells treated with small
molecules antibiotics and antimicrobial peptides with known MoA to the cytological
profiles obtained after treating with ClavA at different conditions. The results presented
three different MoA for ClavA. These mechanisms were found to be not antagonistic with
each other; rather, they are dependent on the pH and local Zn 2+ concentration.
Methodology
Bacterial Cytological Profiling. Bacterial cytological profiling (BCP) was performed
using a procedure adapted from Nonejuie et al.2 All cellular measurements were
performed using ImageJ software, utilizing the freehand selection tool to trace either the
membrane or nucleoid. Each was then measured for area, perimeter, and circularity.
Length and width were measured separately using the straightline selection tool. Average
DAPI and SYTOX Green intensities were measured using the outline of the membrane
and subtracted from the background intensity. The intensities were then normalized
against the intensities from untreated cells measured on the same day with the same
microscope and camera settings. In every case, measurements were made on at least
50 cells, and every cell was measured in each image used, excluding any cells that we
only partially captured.
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Principal Component Analysis. For each antimicrobial treatment, the cell
morphology parameters were obtained from at least three independent experiments. For
each parameter, the average measurement was also calculated and included in the data
set. The parameters were reduced into three orthogonal variables using principal
component analysis (PCA) from our in-house Python scripts. For each treatment, three
cells were selected as representative cells by determining three transformed
measurements with the shortest Euclidean distance from the transformed average
measurement. The cell morphology parameters of the representative cells were used for
PCA of various groups of treatments. Clustering was performed using the Euclidean
distance method from our inhouse Python scripts, where centroids having a distance of
2.4 units or lower are in the same cluster.
Results
Bacterial Cytological Profiles Suggest Multiple Mechanisms of Action. Despite the
compelling evidence indicating that ClavA is capable of cleaving DNA in the presence of
zinc ions, it cannot be ignored that almost all of the published research on the AMP
indicates that it is membrane active.8-10, 13-14 We have shown previously that ClavA has
antimicrobial activity in the absence of zinc ions, which would indicate that ClavA has at
least two MoA depending on the environment of the peptide. In order to further explore
the mechanisms employed by ClavA, we hypothesized that bacterial cytological profiling
(BCP) will allow for the observation and differentiation of the ClavA MoA. BCP is based
on the idea that antibiotics that act on the same pathway or target will likewise cause the
same phenotypic changes in treated bacteria.2 This technique has been previously
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applied to the study of the MoA for small molecule antibiotics and anticancer metal−ligand
complexes.4, 15
The study of the antimicrobial effect of any molecule via BCP begins with
phenotypic analysis of the treated cells. The first step in this process is to collect and
analyze micrographs of E. coli treated with ClavA. The morphology of the bacterial
membranes was measured via staining with FM 4-64 (Figure 4.1, red), and its
permeability was reported by SYTOX green (Figure 4.1, green), a cell impermeable DNA
dye. The cell permeable DNA stain DAPI (Figure 4.1, blue) was also used to identify and
measure nucleoid morphology and multiplicity. These images are analyzed for size and
shape of the membrane and nucleoid as well as the relative intensity of the DNA dyes.
After treating E. coli with ClavA for 60 min at pH 5.5, we observed two distinct
phenotypes (Figure 4.1C). The first phenotype, indicated by the solid white box, was
longer than the untreated E. coli (Figure 4.1A) but maintained the same overall
appearance with a ring of red for the membrane and blue DNA inside. Cells displaying
the second phenotype, indicated by the dashed white box, maintained a similar overall
size to the untreated cells but with a diffuse red signal throughout and with DNA stained
both blue and green. We called these two phenotypes Type A1 and Type A2, respectively,
due to the acidic pH at which they are observed. Approximately 60% of the cells show
Type A1 damage and the remaining 40%, Type A2 after 60 min of treatment. On the basis
of these results, we conclude that, at low pH, ClavA is actually working via two different
MoA.
We hypothesized that these two mechanisms of bacterial damage were based on
exposure time to ClavA. To test this, we modified the treatment time from the original 60
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Figure 4.1. Micrographs of E. coli that have been (A) untreated or treated with (B) ClavA for 30 min, (C)
ClavA for 60 min, (D) ClavA for 120 min, (E) ClavA–Zn(II) for 60 min, and (F) ClavA for 60 min at
neutral pH. Scale bars are 5 μm. Solid white boxes indicate ClavA Type A 1, while dashed white boxes
indicate Type A2.

min to 30 and 120 min, represented by Figure 4.1B,D, respectively. After 30 min of
treatment, the predominant MoA for ClavA is Type A1, with about 80% of cells falling into
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that category. The ratio flips at 120 min, with 75% of the cells exhibiting the Type A 2
phenotype. This would indicate that the initial interaction of ClavA with E. coli results in
Type A1 damage, with Type A2 appearing after, and possibly as a result of, Type A1.
Since ClavA is potentiated by Zn(II) at low pH, we next determined if and how the
addition of Zn(II) affected the phenotype of the treated E. coli. As can be seen in Figure
4.1E, ClavA−Zn(II) treatment results exclusively in damage resembling Type A2. The
visual similarities between E. coli treated with ClavA−Zn(II) and Type A2 damage point to
the likelihood that these two mechanisms are the same and that the Type A2 MoA results
from scavenging Zn(II) ions from E. coli or the media.
Next, we determined if and how these mechanisms differ from the activity of ClavA
at neutral pH since van Kan et al. postulated a different MoA under those conditions,
namely, nonspecific pore formation.10 Figure 4.1F shows cells treated with ClavA at pH
7.4. It can be observed that these cells are longer than either untreated or ClavA Type A1
damaged E. coli and that most (∼88%) of these cells have two nucleoids (Figure 4.1F).
The MoA that resulted in this visually distinct phenotype is referred to as ClavA Type N,
due to the neutral pH at which this phenotype appears.
Identification of Mechanisms of Action through Principal Component Analysis. For
a more quantitative approach to data analysis, we employed principal component analysis
(PCA), which is a statistical treatment that reduces the dimensionality of a large data set,
while minimizing the loss of variance. In this procedure, the set of measurements of
possibly correlated variables are orthogonally transformed into values of uncorrelated
variables, called principal components. The first principal component reflects the variable
with the highest variance, followed by the second principal component with the second
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highest variance, and so on. Commonly, the values of the first, second, and third principal
components are used for presenting the visual 2D and 3D plots. We have elected to use
the 2D plot as the variance in the third dimension was minimal. From the cytological
profiles of the bacterial cells after treating with ClavA at different conditions, three
phenotypes were observed. Figure 4.2 shows a PCA plot of the data pertaining to the
various MoA for ClavA presented above. (Data collected for all treatments and used for
PCA can be found in Tables S4.1 and S4.2.) It is clear from the plot that Type A 1 and
Type N are found in different regions of the plot, while Type A 2 and ClavA−Zn(II) cluster
together. These results corroborate what was found through phenotypic analysis, namely,
that Type A1, Type A2, and Type N mechanisms are all different and that the MoA
corresponding to Type A2 is the same as treatments of a known MoA. When these
established treatments cluster with the treatment of interest, it indicates that their MoA
likely share the same target molecule or pathway. For this study, we used six HDPs with
well-defined MoA: (i) magainin 2, a membrane active HDP known to form toroidal pores
in the membranes of both Gram-positive and Gram-negative bacteria;16-18 (ii) buforin that
of ClavA−Zn(II). PCA can be more informative when used in conjunction with II, an HDP
that binds to DNA after crossing the cellular membrane of bacteria without damaging it;1921

(iii) indolicidin, a nonlytic peptide with an internal target capable of creating pores in the

inner and outer membranes of Gram-negative bacteria;22-23 (iv) ixosin, an HDP that exerts
its activity against the membrane through oxidative damage utilizing bound Cu(II),
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Figure 4.2. PCA plot of the ClavA treatments with model AMPs. The boxes indicate treatments that cluster
together.

resulting in membrane perturbation;24-25 and (v−vi) piscidin 1 and 3, which have been
shown to bind both the membrane and DNA.26 Piscidin 1 interacts more strongly with the
membrane, while piscidin 3 interacts more strongly with DNA. Micrographs for each of
the established HDPs can be found in Figure S4.1.
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On the basis of the varied MoA presented above, it is no surprise that all of our
model peptides localize in different parts of the PCA plot (Figure 4.2). ClavA Type A1
clusters with indolicidin, indicating that Type A1 damage is likely similar to that inflicted by
indolicidin. ClavA Type N clusters with piscidin 1 and 3 but does not cluster with magainin
2. In contrast with both Type A1 and Type N, Type A2 does not cluster with any of the
established peptides and instead only clusters with ClavA−Zn(II).
Discussion
From the PCA and BCP results, the disagreement between the proposed
mechanisms were addressed. Currently, there are two standing mechanisms for ClavA:
(i) it acts on DNA, resulting to growth inhibition,12 and (ii) it is membrane active acting via
a nonspecific pore formation mechanism.10 This is the first time that PCA and BCP was
used to study antimicrobial peptides.1-4 With this, we were able to determine that the three
mechanisms of action of ClavA that were identified are both pH-dependent and Zn2+
concentration-dependent. At neutral pH, the mechanism is similar to piscidin 1, in which
it kills through membrane disruption but without forming magainin-like pores.10 At an
acidic pH, there were two phenotypes identified for the treated bacterial cells, suggesting
that there are two different MoA. These phenotypes were observed in different ratios at
different exposure times to the ClavA treatment. When exposed only for 30 minutes, the
predominant cytological profile, which is Type A1, clusters with that of indolicidin. It is
capable of forming pores without completely lysing the cell, but acts on an internal target
that leads to DNA synthesis inhibition. 22-23 When exposed for a longer time of about 120
minutes, cytological profiles of Type A2 starts to dominate the population and these cluster
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separately from AMPs with established MoA, emphasizing the uniqueness of the DNA
cleaving mechanism proposed for ClavA in the presence of Zn2+.
There are multiple instances in the literature, wherein the proposed MoA are
conflicting. Initially, indolicidin was found to create membrane pores.27 However, recent
studies showed that it binds to DNA, interfering with replication, transcription, and
translation.22 From what was observed with ClavA, it is possible that both MoA are
possible, and will depend on the treatment conditions, including incubation time and
peptide concentration. We hypothesize that conducting a similar BCP experiment and
PCA analysis to indolicidin would result in different phenotypes. Tachyplesin is has been
shown to target different molecules inside the cell, such as LPS, membrane
phospholipids, and DNA.28-31 Piscidin 3 was described in different literatures as being
membranolytic or acting on DNA based MoA.32-34 The fungal defensin, plectasin, has also
been identified to act on two distinct targets: Lipid II for inhibiting cell wall biosynthesis,
and membrane embedded potassium ion channels.35-37 In all these antimicrobial
peptides, BCP and PCA could be used to determining their MoA, especially if these are
dependent on the environmental conditions. One limitation, however, of this method is
that antibiotics with known MoA should be used as standards. If an AMP has a novel
MoA, such as what we have seen in ClavA in the presence of Zn2+, the method can be
used to inform the novelty of the mechanism but it could not describe the mechanism.
Conclusion
We were able to demonstrate that the combined method of bacterial cytological
profiling and principal component analysis can be effectively used to identify the
mechanisms of action of ClavA. A feature that became evident is that varying the
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environmental conditions may result into the AMP having a different mechanism of action.
This suggests that AMPs have the flexibility to kill bacteria at different regions where they
can be expressed or delivered. However, in terms of their therapeutic potential, it is
possible that this versatility is present in how it affects different types of human cells found
in different parts of the body. It is interesting to see the applicability of BCP and PCA in
treating human cells under different conditions.
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Chapter 5

Metadynamics as a Tool to Evaluate Relative Free Energies
of SF2312, an Unbinding of Inhibitor of E. coli Enolase

Adapted in part from:
Krucinska, J., Lombardo, M. N., Erlandsen, H., Hazeen, A., Duay, S. S., Pattis, J. G.,
Robinson, V. L., May, E. R., Wright, D. L.
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Introduction
In the previous chapters, we discussed how different computational techniques
and statistical analyses can be used on antimicrobial peptide systems to validate
empirical results and support the existing conclusions. In this chapter, we employed
metadynamics simulations on Escherichia coli enolase to understand the basis of the
experimentally obtained binding affinities of two different substrates to the enolase.
Enolases (EC 4.2.1.11) are enzymes that catalyze dehydration of 2phosphoglycerate (2-PGA) to phosphoenolpyruvate (PEP) (Figure 5.1).1 The mechanism

Figure 5.1. (A) Conversion of 2-phosphoglycerate to phosphoenolpyruvate catalyzed by enolase. (B)
Inhibitors for E. coli enolase used in this study.
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of this reaction involves formation of an intermediate carbanion.2-3 This reaction is part of
the glycolytic pathway that produces adenosine triphosphate (ATP), the energy currency
of living organisms. In some bacteria such as Streptococcus canis and Streptococcus
pneumoniae, enolases enhance bacterial resistance, invasiveness, and tissue damage. 45

Thus, this protein can be targeted for inhibition to affect the viability and pathogenicity

of bacteria that cause infectious diseases.
In E. coli, an enolase complexed with its substrate 2-PGA was recently crystallized
and characterized.6 In this study, antimicrobial tropolones were identified to be targeting
E. coli enolase, providing an evidence that enolase inhibition can be targeted to develop
antibacterial compounds.6 Another compound, SF2312, was isolated as a natural
phosphonic acid antibiotic, and was found to have anticancer activity in humans. 7 This
activity is due to the inhibition of human enolase ENO2, which causes deletion of human
enolase ENO1.7 The compound is an analog of the carbanion intermediate formed upon
dehydration of 2-PGA. The mechanism of action of its antibacterial activity is via active
transport across the bacterial cell envelope, followed by inhibition of bacterial enolase. 8
Oxidation of the SF2312 C5 hemiaminal moiety to an imide carbonyl produces KSF, and
this resulted to weaker inhibition of the enolase activity. 8 SF2312 has a stronger affinity
than KSF, as determined from their inhibitory constants K i.8 This also revealed that
SF2312 is an analog of the carbanion intermediate formed upon dehydration of 2-PGA,
explaining its effectivity as an enolase inhibitor. 8
In this chapter, we conducted metadynamics simulations to explore unbinding
pathways of SF2312 and KSF from their individual enolase-bound states. The relative
residence times observed experimentally were confirmed through these simulations. We
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also generated free energy profiles from the identified unbinding pathways that explained
the stronger binding affinity seen for SF2312. The simulations also showed the role of
Mg2+ ion in stabilizing SF2312 in the active site of the enolase.
Methodology
Systems were initially equilibrated first for 100ns in the NPT ensemble, during
which no significant changes in the protein (RMSD <1.7Å) and the ligand (RMSD <0.25Å)
are observed. The equilibrium KSF simulations were initiated from chain F monomer of
the enolase:KSF crystal structure, while the equilibrium SF2312 simulations were initiated
from the chain A monomer of the enolase:SF2312 crystal structure. Missing residues in
enolase of the enolase:KSF crystal structure were built-in by aligning to the
enolase:SF2312 structure and copying in the coordinates from the SF2312 system. The
systems were solvated with the TIP3P water model and 150mM NaCl, and protonation
states of the amino acid residues were based upon model system pKas at pH 7. The
ligand parameters were obtained using CGenFF9-10 (https://cgenf.umaryland.edu) and
CHARMM36m force field11 was used for the protein and solvent components. All
simulations were performed using the GROMACS 2018 program12. Energy minimization
and equilibration steps were performed according to the CHARMM-GUI protocol, running
500 steps of steepest descent minimization and six steps of canonical ensemble
equilibrations for 25 ps each with 1 fs timestep. Positional restraints were applied on the
heavy atoms, gradually decreasing the force constants after every equilibration step. The
systems were run again for 100 ns using a timestep of 2 fs. Temperature was maintained
at 300K using the Nose-Hoover thermostat13-14 with coupling time constant of 1ps.
Pressure was maintained at 1bar through isotropic pressure coupling with a coupling
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constant of 5 ps, using the Parrinello-Rahman barostat15. Van der Waals interactions
were cut off at 12Å, with interactions modified using the force-switch method between 10
and 12Å. Long-range electrostatic interactions were calculated using the particle mesh
Ewald method, with real-space cutoff of 1.2 nm.
Metadynamics simulations were initiated from the final structure of each
equilibrated system. We performed metadynamics using the frequency-adaptive
metadynamics scheme16 from the open-source, community-developed PLUMED library,
version 2.517. In order to carry out a successful transition between bound state and
unbound state in all systems, a suitable collective variable (CV) must be carefully chosen.
In our systems, the collective variable is the distance between the COM of the ligand and
the COM of six residues on the β-barrel of the protein. The β-barrel COM coordinate was
defined by the side chain heavy atoms of residues Glu167, Asp245, Glu289, Asp316,
Lys341, and His369 (Figure 5.2A). Ten independent simulations each of the KSF and
SF2312 without Mg2 systems, while eleven independent simulations of the SF2312 with
Mg2 system exhibited successful unbinding of the ligand, which were used for further
analyses. The intermittently added Gaussian functions added to carry out frequencyadaptive metadynamics is stored in a file called HILLS. In this file, the CV distance every
10ps is reported. Because the unbinding time of the ligand varies in each independent
simulation, we chose 7.0 nm as a safe CV distance to consider the ligand to be in the
unbound state. Thus, we trimmed each HILLS file such that the last datapoint is when the
ligand first crosses the 7.0 nm CV distance. There are some simulations where the ligand
did not reach the 7.0 nm CV distance (lowest is 5.47 nm), but regardless, the ligand has
still reached the unbound state in those instances. This is then used as an input to a post-
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Figure 5.2. (A) The CV for metadynamics is represented by the distance (black line) between the COM of
the ligand (orange sphere) and the COM of the labeled residues (blue sphere), excluding residue Asp317.
(B) Relative free energy profiles of unbinding for KSF, SF2312 with Mg2, and SF2312 without Mg2, insert
figure shows a zoomed in PMF in the range from 0.3–1.5 nm in the CV. The bound configuration of
SF2312 is shown in (A), while representative structures of the first and second energy barriers are shown
in panels (D,C), respectively. In panels (A,C,D) the Mg2+ ions are represented as purple spheres, Asp317
is shown in yellow and SF2312 is shown in orange.

processing method called sum_hills to reconstruct the free energy function. To assess
reliability of the calculated metadynamics unbinding time distribution and to determine the
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characteristic unbinding times for each system, a two-sample Kolmogorov-Smirnov (KS)
test18 was performed a posteriori as implemented in Matlab R2018a 19-20. This test
determines whether the empirical cumulative distribution function obtained from
calculations is similar to a theoretical Poisson cumulative distribution function 16, 18.
Results and Discussion
The relative free energies of unbinding of SF2312 and KSF from enolase were
obtained by running frequency adaptive metadynamics simulations. To generate ligand
unbinding trajectories, the simulations were biased along a collective variable (CV), which
describes the ligand dissociation coordinate. A single CV was chosen which was the
distance between the ligand center-of-mass (COM) and the collective COM of six
residues (E167, D245, E289, D316, K341, H369) on the β-barrel of enolase, below the
binding site (Figure 5.2A). From each unbinding trajectory a free energy profile (potential
of mean force, PMF) is obtained and the individual PMFs are then averaged (Figure 5.2B).
It was observed that the PMF profiles were qualitatively different for SF2312 and KSF
unbinding. The KSF profile indicates a one-step process with a single energy barrier
around 0.6 nm in the CV and barrier height around 65 kJ/mol. The SF2312 PMF also
displays an energy barrier in a similar location and of similar height to the KSF barrier,
however, SF2312 displays a large basin following the first barrier. The basin extends out
to approximately 1.7 nm in the CV and the height of the barrier is considerably larger than
first barrier (>100 kJ/mol). From these PMFs it can be inferred that the rate-limiting step
in the dissociation of SF2313 would be the second energy barrier and would indicate a
longer residence time for SF2312 than the KSF.
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Interestingly, from the trajectories of the SF2312 simulations, it was observed that
one of the Mg2+ ion (from hereon, will be referred to as Mg2) in the active site dissociates
concomitantly with the inhibitor (Figure 5.3). The first energy barrier is characterized by
loop opening, and the ligand and Mg2 becoming more exposed to the solvent (Figure
5.2D). In all eleven trials, we observed that the Mg2 and Asp317 have sustained
interactions in the metastable state and the second energy barrier appears to be arising
from breaking this contact to fully release SF2312 from the protein (Figure 5.2C). We
quantified which residues come into contact with Mg2 during the simulation, using a 4 Å
cutoff distance, and find that Asp317 has the most consistent interactions and is the last
residue to be in contact with Mg2 before dissociation (Figure 5.4). To test the importance
of Mg2 in stabilizing the interaction of SF2312 with enolase, we ran another set of
metadynamics simulations with Mg2 removed from the system. We find that the PMF for
SF2313 without Mg2, more closely resembles the KSF PMF and does not display the
metastable state and second energy barrier.
From the metadynamics simulation time of unbinding (see Figure 5.5 and Table
5.1), we observe KSF has the shortest characteristic time of unbinding, followed by
SF2312 without Mg2, and SF2312 with Mg2 has the longest characteristic unbinding time.
Relating these simulation times directly to experimental residences times would require a
rescaling procedure21 or a different set of simulation parameters (non well-tempered)22.
However, the metadynamics unbinding times are qualitatively consistent with the
experimental residence times and support that SF2312 has a greater residence time in
enolase than that of KSF.
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Figure 5.3. Distances between the binding site COM and the inhibitor COM, Mg1 and Mg2 over the
time course of the eleven metadynamics trajectories for SF2312 with both Mg 2+ ions. In all trials, except
trail 5, SF2312 and Mg2 positions are highly correlated, indicating they are strongly interacting through
the inhibitor dissociation pathways.
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Figure 5.4. Distances of residues that are within 4 Å radius of Mg2 on each trial. The residues are Ser41,
Asp290, Asp316, and Asp317. A heat map from red, indicating 0.0 nm distance, to purple, indicating 0.4
nm distance, was used. Absence of color means that the residue is not within 4 Å radius of Mg2. Asp317
is the last residue to be in contact with Mg2 before SF2312 completely unbinds.
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Figure 5.5. Results of the Kolmogorov-Smirnov (KS) test from the transition times of the first energy
barrier (CV = 0.7 nm) (A) and second energy barrier (CV = 2.1 nm) (B). Probability of observing at least
one transition by time t evaluated from the simulations (thin lines) and fitted as a Poisson process (thick
lines).

Conclusion
Through metadynamics simulations, the stronger affinity of SF2312 over its
oxidized analog, KSF, can be mainly attributed to the presence of an additional Mg 2+ ion
(Mg2) in the active site of the SF2312-bound enolase. This extra Mg2+ ion was not present
in the crystal structure of the KSF-bound enolase. Furthermore, the only Mg2+ ion in the
KSF-bound enolase did not seem to play any role in the stability of the ligand binding.
Mg2 prevented the ligand from leaving the bound state by maintaining long-range
electrostatic attraction with the carboxyl oxygen of Asp317 in the active site, while being
bound to the phosphate oxygen of SF2312. This crucial interaction, in fact, provided an
energy barrier that is higher in magnitude than the energy barrier of breaking the native
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Table 5.1. Simulations of the transition between bound and unbound states of the ligand. Mean transition
time μ, standard deviation σ, and characteristic time τ are reported with the μ/σ and (μ ln 2)/tm ratios. The
p-values from the KS statistics are also reported and p-value of less than 0.05 indicates significant difference
between empirical cumulative distribution function (CDF) and theoretical CDF.
1st Energy Barrier

2nd Energy Barrier

KSF

SF2312 w/
Mg2

SF2312
w/o Mg2

KSF

SF2312 w/
Mg2

SF2312
w/o Mg2

μ (ns)

9±4

28 ± 3

22 ± 4

13 ± 4

60 ± 10

25 ± 4

σ (ns)

13

11

13

13

35

12

tm (ns)

5

26

20

8

47

25

μ/σ

0.69

2.55

1.64

1.00

1.72

1.98

(μ ln 2)/tm

1.40

0.72

0.77

1.07

0.88

0.67

τ (ns)

8.8

37.2

25.4

13.5

70.7

28.4

0.475

0.338

0.298

0.419

0.060

0.132

p-value

interactions with the residues in the active site. We have also seen how metadynamics
simulations can be used to analyze kinetic parameters, such as characteristic unbinding
times, that correlated well with the experimental residence times. However, this requires
multiple independent simulations to provide statistical confidence on the calculated times.
Finally, we demonstrated the ability of metadynamics to access the unbinding of SF2312
starting from a Mg2-absent state, which is inaccessible in the experimental assays
previously conducted. This provided stronger support to the significance of Mg2 in
stabilizing the bound conformation of SF2312.
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Putting Together the Clavanin A Story from a Computational Lens
In developing a therapeutic agent, it is not only important that it is known to be
effective. It is also crucial to understand how it works from a molecular perspective, and
how it physically or chemically interacts with other biomolecules that it will encounter.
Since the discovery of the first AMPs from the giant silk moth Hyalophora cecropia,1-2
there is a growing interest in understanding and developing antimicrobial peptides as
therapeutic agents. Currently, there are about 3,000 AMPs listed in the Antimicrobial
Peptide Database but only a few of them have been studied using computational
techniques.3 The importance of molecular dynamics simulations in understanding the
mechanism of AMPs was established by earlier works on magainin, 4 piscidin,5-7 and
melittin,8-12 to name but a few. These simulations validated conclusions from experimental
results by describing the atomistic details of the mechanism of action of the AMPs. The
membranolytic activity of piscidin 1, for example, was shown to occur by the peptide
inducing surface defects in the membrane, instead of forming long-lived pores.7 The
negatively charged lipids in the composition of a bacterial cell membrane became an
advantage for this peptide as they stabilize the formation of transient pores to help in
translocating the peptide.7 MD simulations also revealed the binding interactions between
piscidin 3 and DNA, supporting the DNA-based mechanism of action proposed for piscidin
3.6 Free energy calculations of physical processes of AMPs in the membrane were also
conducted through MD simulations.8, 10
This dissertation contributes a new body of knowledge about Clavanin A that
cannot be accessed by experimental techniques. Prior to the studies in this dissertation,
all information that was known for Clavanin A were obtained from experimental
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observations. The two general mechanisms of action for AMPs, i.e. membranolytic and
action an internal cell target, were both proposed for Clavanin A from different studies. 1317

In these studies, it was also shown that decreasing the pH of the environment or binding

Zn2+ to the HXXXH motif enhanced the antimicrobial activity of Clavanin A. However, very
little is actually known on how it interacts with the membrane, how it translocates across
the membrane, and what molecular mechanisms contribute to the observed activity
enhancements. The results that were presented in this dissertation addressed these
important points.
In Chapter 2, it was shown how positive charges on Clavanin A significantly
increased the interaction of Clavanin A with the bacterial model membrane, particularly
with the negatively charged POPG lipids. These positive charges can be introduced to
Clavanin A by decreasing pH or by binding Zn2+ to its HXXXH motif. The lability of the
four His residues in Clavanin A to be protonated and deprotonated within the range of
biologically relevant pH allowed the peptide to have a different mode of interaction with
the lipid bilayer. The stabilizing effect of Zn2+ in the helical conformation of the C-terminal
region acting as a structural staple suggested that the helical structure of Clavanin A is
important in potentiating its antimicrobial activity. The Zn2+-bound state of the peptide also
allowed for longer and more favorable interactions of the C-terminal region of the peptide
than that of the N-terminal region, highlighting the important role of Zn2+ binding to the
HXXXH motif of the peptide. Aside from the effect of Zn2+ on Clavanin A and its interaction
with the membrane, the ability of Zn2+ to cause easier membrane deformation was also
observed. This makes it easier for Clavanin A to insert into the bilayer if the membrane
can easily be deformed. The role of Phe residues in penetrating the lipid bilayer deeper
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than other residues supported the significance of the abundant Phe residues shown
experimentally. It was suggested that these residues provide balanced hydrophobicity,
membrane affinity, and conformational flexibility for the peptide to easily insert into the
membrane.18 Finally, we presented a domino-effect model that could explain the effect of
Zn2+ on the enhancement of antimicrobial activity of Clavanin A. In this model, Zn2+
increases the net positive charge on Clavanin A, pulls it closer to the membrane, and
increases the effective concentration of the peptide on a local region of the membrane.
Upon stable interaction of the peptide with the lipid headgroups, the Zn 2+ ion is released
from the peptide resulting in an increase in the deformability of the membrane. As a
consequence, the peptide can insert into the bilayer.
In Chapter 3, we looked at different pathways of translocating Clavanin A across
a complex model of an E. coli outer membrane. Most of the pathways that resulted into
successful translocation of ClavA caused a large membrane perturbation, wherein the
lipids from the upper leaflet are pulled by ClavA to the lower leaflet. As the polar
headgroups traverse the nonpolar region of the lipid bilayer, it can lead to instability of the
system and high energetic states. If the peptide enters the cell without disrupting the
membrane, there must be a mechanism in which it will not cause huge membrane
deformations. From the ΔG values that were calculated, it was concluded that either the
ClavA inserts into the outer membrane as an oligomeric unit or that it enters the cell
through a transport membrane protein. From the transmembrane state to surface-bound
state pathways, it was shown that the peptide at neutral pH prefers to be in a
transmembrane state more than the peptide at an acidic pH. This suggests that pore
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formation, whether it is transient or long-lived, is more favorable for the peptide when it is
at a neutral pH.
Finally, in Chapter 4, principal component analysis was used as a tool in
conjunction with bacterial cytological profiling to address the conflicting mechanisms
proposed for Clavanin A. It was shown that the mechanisms are all true for Clavanin A,
but will depend on the environmental pH and concentration of Zn2+ present. At a neutral
pH, it was identified that Clavanin A acts via membranolysis, similar to piscidin 1. At an
acidic pH, it acts on two internal cell targets, depending on the time of exposure of the
cells to Clavanin A. At shorter exposure times, it forms pores without lysing the cell, then
acts on a cell target that inhibits DNA synthesis, similar to the mechanism of indolicidin.
At longer exposure times, it was able to cleave DNA, a mechanism that is novel among
the antimicrobial peptides that were subjected to the bacterial cytological profiling. This
mechanism is also consistent with the mechanism of Clavanin A when it is bound to Zn2+.
Overall, these results are in good agreement with the results from the previous chapters.
It shows the versatility of Clavanin A, in terms of having multiple mechanisms of killing,
that is responsive on the environmental conditions present. Having multiple ways to kill
pathogenic bacteria is an important property for an antimicrobial compound to combat
antibiotic resistance. This was exhibited by Clavanin A, making it a good potential
candidate to be developed as a therapeutic agent for antibiotic resistance.
Molecular Dynamics Simulations as a Tool in Studying the Interface of Metal Ions
and Proteins
In Chapters 2 and 5, we presented how molecular dynamics simulations can be
used in studying systems of metal-binding proteins or metal-binding antimicrobial
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peptides. One of the hurdles in advancing computational studies in metal ion-containing
systems is the lack of simplicity in the available force fields or computational techniques
to study them. A recent comprehensive review by Merz, et. al., shows that there are a
plethora of force fields and techniques available, ranging from classical modelling, use of
quantum mechanics for parametrization, to polarizable force fields.19 These methods are
too specialized and sophisticated that one must determine if the method is applicable to
the system under study. It is good that simple classical force fields can still be used to
model metal ion-containing systems, but the use of more complicated techniques that will
provide more accurate results is always better. Thus, with the advent of metal ions being
significant in the activity of antimicrobial peptides, it will be interesting for the community
of computational scientists to revisit the development of simpler methodologies that will
provide more accurate results for metal-containing proteins.
Perspectives
The story of the Clavanin A does not end here. In fact, the findings in this
dissertation opened up more questions. Particularly, the free energy difference between
the monomeric translocation of ClavA and its oligomeric transition was unanswered and
will be pursued as a future direction of the project. The interaction of ClavA in membrane
proteins that are present in the outer membrane of E. coli must also be investigated. If
the peptide still requires high free energy for translocating even in oligomeric states, it is
possible that it enters via membrane proteins or it uses other sites that are rich in other
lipids such as cardiolipin. Once the peptide crosses the outer membrane of a Gramnegative bacteria, what is its mechanism in crossing the inner membrane which has a
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very different lipid composition than the outer membrane? These are some of the
questions that can be addressed by doing more computational studies on Clavanin A.
On a larger scale, the need to understand the mechanism of other antimicrobial
peptides with common motifs is pressing. It is important that we understand how these
motifs interact with the membrane or with other biomolecules in performing its function of
killing bacteria. It is important that we identify which conserved motifs do not play a role
in the mechanism of killing. These positive and negative results are equally important,
especially that there is a movement in using artificial intelligence or machine learning
techniques in exploring the antimicrobial peptide sequence space to predict effective
AMPs faster.20 Results from MD simulations can be used in complement with machine
learning to provide functional descriptors that can be used for training machine learning
models. In return, the predicted AMP sequences can be tested experimentally and
computationally to verify if the desired function and mechanism of AMP is present. The
quicker response of the scientific community in designing and developing drugs to
overcome the current problem of antibiotic resistance is necessary.
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Figure S2.1. Superposition of ClavA structures in TFE. MD structure (blue) is overlaid
with the NMR determined structure (PDBID:6C41) (yellow)
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Figure S2.2. Number of contacts that the Zn(II) is making with other species in the
system, including peptide residues, water molecules, and ions, for the ClavA-Zn(II) in
solution simulations. A distance cutoff of 2.2 Å is considered in determining the number
of contacts.
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Figure S2.3. Secondary structure evolution using DSSP analysis for all three trials of
ClavA-Zn(II) in 150 mM NaCl at 300 K
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Figure S2.4. Secondary structure evolution using DSSP analysis for all three trials of
ClavA-Zn(II) in 150 mM NaCl at 320 K.
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Figure S2.5. Secondary structure evolution using DSSP analysis for all three trials of
ClavA-Zn(II) in 150 mM NaCl at 340 K.
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Figure S2.6. Secondary structure evolution using DSSP analysis for all three trials of
ClavA-Zn(II) in 150 mM NaCl at 360 K.
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Figure S2.7. Secondary structure evolution using DSSP analysis for all three trials of
ClavA in 150 mM NaCl at 300 K.
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Figure S2.8. Secondary structure evolution using DSSP analysis for all three trials of
ClavA in 150 mM NaCl at 320 K.
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Figure S2.9. Secondary structure evolution using DSSP analysis for all three trials of
ClavA in 150 mM NaCl at 340 K.
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Figure S2.10. Secondary structure evolution using DSSP analysis for all three trials of
ClavA in 150 mM NaCl at 360 K.
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Figure S2.11. Secondary structure evolution using DSSP analysis for all three trials of
simulations initiated from helical ClavA placed 3 nm above the membrane.
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Figure S2.12. Secondary structure evolution using DSSP analysis for all three trials of
simulations initiated from helical ClavA with Zn(II) restrained to His17 and His21 placed
3 nm above the membrane.
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Figure S2.13. Secondary structure evolution using DSSP analysis for all three trials of
simulations initiated from helical ClavA, with 32 Zn(II) ions unrestrained, placed 3 nm
above the membrane.
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Figure S2.14. (A) In one simulation of ClavA-Zn(II) in the presence of the E. coli outer
membrane mimic, a stable

-helix was formed from residues Lys7 to Val12. To confirm

if this was due to Zn(II), the last snapshot (500 ns) was extracted from the trajectory. The
Zn(II) ion was then removed from the system and the simulation was continued for
another 500 ns, shown in (B). The region remained α-helical, thus, we suspect the
membrane induced the

-helical formation and not the Zn(II).
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Figure S2.15. Insertion depth profile of ClavA in the presence of an E. coli outer
membrane mimic at pH 7 (Trial 1).
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Figure S2.16. Insertion depth profile of ClavA in the presence of an E. coli outer
membrane mimic at pH 7 (Trial 2).
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Figure S2.17. Insertion depth profile of ClavA in the presence of an E. coli outer
membrane mimic at pH 7 (Trial 3).
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Figure S2.18. Insertion depth profile of ClavA in the presence of an E. coli outer
membrane mimic at pH 5 (Trial 1).
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Figure S2.19. Insertion depth profile of ClavA in the presence of an E. coli outer
membrane mimic at pH 5 (Trial 2).
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Figure S2.20. Insertion depth profile of ClavA in the presence of an E. coli outer
membrane mimic at pH 5 (Trial 3).
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Figure S2.21. Insertion depth profile of ClavA-Zn(II) in the presence of an E. coli outer
membrane mimic at pH 7 (Trial 1).
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Figure S2.22. Insertion depth profile of ClavA-Zn(II) in the presence of an E. coli outer
membrane mimic at pH 7 (Trial 2).
153

Figure S2.23. Insertion depth profile of ClavA-Zn(II) in the presence of an E. coli outer
membrane mimic at pH 7 (Trial 3).
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Figure S2.24. Insertion depth profile of ClavA-Zn(II) in the presence of an E. coli outer
membrane mimic at pH 5 (Trial 1).
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Figure S2.25. Insertion depth profile of ClavA-Zn(II) in the presence of an E. coli outer
membrane mimic at pH 5 (Trial 2).
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Figure S2.26. Insertion depth profile of ClavA-Zn(II) in the presence of an E. coli outer
membrane mimic at pH 5 (Trial 3).
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Figure S2.27. Clavanin A at pH 7 in the absence of Zn(II). Initial approach of the
longest binding event for each terminal region in all three trials.
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Figure S2.28. Clavanin A at pH 7 in the presence of Zn(II). Initial approach of the
longest binding event for each terminal region in all three trials.
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Figure S2.29. Clavanin A at pH 5 in the absence of Zn(II). Initial approach of the
longest binding event for each terminal region in all three trials.
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Figure S2.30. Clavanin A at pH 5 in the presence of Zn(II). Initial approach of the
longest binding event for each terminal region in all three trials.
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Figure S2.31. At pH 5, (A) the survival binding probabilities are compared between the
N-terminal region and the C-terminal region for systems with Zn(II) unbound and Zn(II)
bound. (B) The survival binding probabilities are also compared between the systems
with Zn(II) unbound and with Zn(II) bound for the N-terminal region and the C-terminal
region. The N-terminal region of ClavA binds longer when Zn(II) is absent. No significant
differences were found on all other comparisons.
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Figure S2.32. Ratio of POPE interactions to POPG interactions of each residue
normalized against the bulk ratio of POPE:POPG (4:1) in the model membrane. Bars
represent the average of three trials ± the standard error of the mean. The amino acid
sequence of Clavanin A is written at the bottom, with blue and red letters indicating
nonpolar and polar residues, respectively.
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Figure S2.33. Heat maps showing the number of POPG lipids around each residue within
4 Å radius over the 500 ns simulation. In these simulations, Zn(II) is restrained to His17
and His21 of ClavA at two different pHs.
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Figure S2.34. Probability density heat maps of POPG lipids around each residue within
a 4 Å radius at pH 7. Each circle represents a 4 Å circle along the xy plane of the
membrane, with the center of the circle representing the center of mass of each residue
side chain. The color spectrum runs from white to violet, indicating zero density to highest
density.
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Figure S2.35. Probability density heat maps of POPG lipids around each residue within
a 4 Å radius at pH 5. Each circle represents a 4 Å circle along the xy plane of the
membrane, with the center of the circle representing the center of mass of each residue
side chain. The color spectrum runs from white to violet, indicating zero density to highest
density.
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Figure S2.36. Calculated compressibility modulus values using different timescales on
the last 400 ns of the zinc(II)-membrane simulations. Black squares indicate the first 200
ns window, red circles indicate the last 200 ns window, blue triangles indicate the last 300
ns window, and green inverted triangles indicate the last 400 ns window.
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Figure S2.37. (A) Area per lipid of no Zn(II) and 1:7.5 Zn(II):lipid systems, subjected to
different lateral pressures. It took 40 ns to reach equilibration of the area per lipid. (B)
Surface tension-area per lipid isotherms at 300 K for the two systems.
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Figure S2.38. Interaction of ClavA-Zn(II) with lipid bilayer membrane and water
molecules (shown in circles) present on the surface of the lipid bilayer membrane.
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Figure S2.39. Sequence alignment of the clavanins from the tunicate Styela clava. The
phenylalanine residues are highly conserved (highlighted in red).

170

Figure S2.40. Sequence of peptides that have enhanced antimicrobial activity in the
presence of Zn(II). HXXXH motif is present in all the peptides identified with increased
except for the OVPSAAP peptides.

171

Figure S4.1. Representative micrographs of E. coli treated with (A) Buforin II, (B)
Indolicidin, (C) Ixosin, (D) Magainin 2, (E) Piscidin 1, and (F) Piscidin 3. Scale bars
represent 5 μm.
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Table S4.1. Average morphology measurements of treated bacterial membranes
Area

Perimeter

Length

Width

(μm2)

(μm)

(μm)

(μm)

3.787

8.532

3.287

1.239

0.658

1.333

3.272

7.933

2.961

1.072

0.667

1.229

5.557

11.336

4.641

1.278

0.550

1.873

3.443

7.574

2.823

1.173

0.752

1.063

Buforin II

3.656

8.399

3.328

1.160

0.653

1.000

Indolicidin

4.683

9.566

3.798

1.211

0.652

1.226

Ixosin

2.448

6.687

2.444

1.046

0.692

1.271

Magainin 2

6.602

13.018

5.439

1.285

0.503

1.600

Piscidin 1

5.510

11.785

4.792

1.172

0.516

1.342

Piscidin 3

4.996

10.914

4.436

1.145

0.539

1.449

Treatment

Nucleoids/
Circularity
Cell

Clavanin A
Type A1
Clavanin A
Type A2
Clavanin A
Type N
ClavAZn(II)
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Table S4.2. Average morphology measurements of treated bacterial nucleoids.
Area
Treatment

(μm2)

Perimeter

(μm)

Length

Corrected

Corrected

SYTOX

DAPI

Intensity

Intensity

Width

(μm)

(μm)

Circularity

Clavanin A
1.288

4.845

1.967

0.693

0.677

1.285

2.869

1.746

5.641

2.083

0.845

0.688

15.165

3.626

1.425

5.068

1.919

0.775

0.701

1.005

0.842

ClavA-Zn(II)

2.476

6.643

2.480

0.945

0.702

15.644

2.430

Buforin II

1.712

5.868

2.339

0.739

0.635

1.280

1.674

Indolicidin

1.633

5.965

2.535

0.609

0.582

1.023

1.929

Ixosin

0.738

3.696

1.364

0.652

0.678

5.096

1.526

Magainin 2

2.173

7.038

2.886

0.743

0.559

1.069

1.349

Piscidin 1

1.816

6.838

2.902

0.675

0.519

1.108

1.299

Piscidin 3

1.852

6.270

2.371

0.735

0.604

1.122

0.929

Type A1
Clavanin A
Type A2
Clavanin A
Type N
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Table of AMPs other than clavanin A mentioned in the dissertation.
α-defensin 4
AKK24
ARK24
androctonin
buforin II
cecropin P1
chensinin 1
gaduscidin-1
gaduscidin-2
indolicidin
ixosin
KS-30
LL-37
magainin 2
nisin A
piscidin 1
piscidin 3
plantaricin
protegrin
PR-39
RK-31
tachyplesin
tritrpticin

VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV
AKKARAAKKARAAKKARAAKKARAAKKARAAKKARA
ARKKAAKAARKKAAKAARKKAAKA
RSVCRQIKICRRRGGCYYKCTNRPY
TRSSRAGLQFPVGRVHRLLRK
SWLSKTAKKLENSAKKRISEGIAIAIQGGPR
IGVIKLSLCEEERNADEEKRRDDPDEMDVEVEKR
MRYIVLLVVVLLLAMMVQPADCFIHHIIGWISHGVRAIHRAIHGEKAEE
YIMVD
MRCIFLLFVVLLLAMMVLPAEGFLHHIVGLIHHGLSLFGDRADKAEEYI
AVD
ILPWKWPWWPWRR
GLHKVMREVLGYERNSYKKFFLR
KSKEKIGKEFKRIVQRIKDFLRNLVPRTES
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
GIGKFLHSAKKFGKAFVGEIMNS
ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK
FFHHIFRGIVHVGKTIHRLVTG
FIHHIIGGLFSVGKHIHSLIHGH
KPAWCWYTLAMCGAGYDSGTCDYMYSHCFGVKHSSGGGGSYHC
RGGRLCYCRRRFCVCVGR
RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP-NH2
RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
KWCFRVCYRGICYRRCR
VRRFPWWWPFLRR
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